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Background: Not all stroke survivors respond to the same form of physical therapy in the same way early
after stroke. The response is variable and a detailed understanding of the interaction between specific
physical therapies and neural structure and function is needed.
Objectives: To determine if upper limb recovery is enhanced more by functional strength training (FST)
than by movement performance therapy (MPT), to identify the differences in the neural correlates of
response to (1) FST and (2) MPT and to determine whether or not pretreatment neural characteristics can
predict recovery in response to (1) FST and (2) MPT.
Design: Randomised, controlled, observer-blind, multicentre trial with embedded explanatory investigations.
An independent facility used computer-generated randomisation for participants’ group allocation.
Setting: In-patient rehabilitation, participants’ homes, university movement analysis facilities and NHS or
university neuroimaging departments in the UK.
Participants: People who were between 2 and 60 days after stroke in the territory of the anterior cerebral
circulation, with some voluntary muscle contraction in the more affected upper limb but not full function.
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Interventions: Routine rehabilitation [conventional physical therapy (CPT)] plus either MPT or FST in equal
doses during a 6-week intervention phase. FST was progressive resistive exercise provided during training
of functional tasks. MPT was therapist ‘hands-on’ sensory input and guidance for production of smooth
and accurate movement.
Main outcomes: Action Research Arm Test (ARAT) score for clinical efficacy. Neural measures were made
of corticocortical [fractional anisotropy (FA) from corpus callosum midline], corticospinal connectivity
(asymmetry of corticospinal tracts FA) and resting motor threshold of paretic biceps brachii (pBB) and
extensor carpi radialis muscles (derived from transcranial magnetic stimulation).
Analysis: Change in ARAT scores were analysed using analysis of covariance models adjusted for baseline
variables and randomisation strata. Correlation coefficients were calculated between change in neural
measures and change in ARAT score per group and for the whole sample. An interaction term was
calculated for each baseline neural measure and ARAT score change from baseline to outcome.
Results: A total of 288 participants were randomised [mean age 72.2 (standard deviation 12.5) years;
mean ARAT score of 25.5 (18.2); n = 283]. For the 240 participants with ARAT measurements at baseline
and outcome, the mean change scores were FST + CPT = 9.70 (11.72) and MPT + CPT = 7.90 (9.18). The
group difference did not reach statistical significance (least squares mean difference 1.35, 95% confidence
interval –1.20 to 3.90; p = 0.298). Correlations between ARAT change scores and baseline neural values
ranged from –0.147 (p = 0.385) for whole-sample corticospinal connectivity (n = 37) to 0.199 (p = 0.320)
for MPT + CPT resting motor threshold pBB (n = 27). No statistically significant interaction effects were
found between baseline neural variables and change in ARAT score. There were no differences between
groups in adverse events.
Limitations: The number of participants in the embedded explanatory investigation was lower
than expected.
Conclusions: The small difference in upper limb improvement in response to FST and MPT did not reach
statistical significance. Baseline neural measures neither correlated with upper limb recovery nor predicted
therapy response.
Future work: Needs to continue investigation of the variability of response to specific physical therapies in
people early after stroke.
Trial registration: Current Controlled Trials ISRCTN19090862 and National Research Ethics Service
reference number 11/EE/0524.
Funding: This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical
Research Council and National Institute for Health Research partnership.
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Plain English summary
Recovery of the arm and hand (upper limb) after stroke is a research priority. We need to know whichpeople should receive which type of physical therapy and how different types of physical therapy drive
brain recovery after stroke.
The two physical therapies investigated were functional strength training (FST) and movement performance
therapy (MPT). FST is strength training during everyday tasks, for example picking up a cup that contains
more water as the person improves. MPT is provided by a therapist using ‘hands-on’ techniques to aid
moving more smoothly and accurately.
Random allocation was used so that each participant had a 50% chance of receiving FST or MPT. All
participants undertook measures of ability to move their upper limb before treatment, after the 6-week
treatment phase and at 6 months after stroke. In participants with no history of epilepsy/seizures and no
metal in their bodies (e.g. pacemaker) we undertook measures of (1) the brain damage caused by stroke
and (2) the strength of the connection between brain and weak muscle. These neural measures were
carried out before and after the treatment phase.
We found no difference between FST and MPT because some people in each group responded better
than others.
The before-treatment neural measures did not predict improvement. The neural changes from before to
after treatment were similar in the two groups.
These findings confirm suggestions from earlier trials that people respond differently to different physical
therapies. Future work should investigate why some people respond better to FST and MPT than others.
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Scientific summary
Background
The trial reported here focused on the top 10 research priorities identified by people who have had a
stroke, namely upper limb recovery after stroke. This is because of the need for upper limb dexterity to
perform everyday tasks, such as drinking from a cup, unscrewing the top from a bottle of water and
fastening buttons/zips, for independent living. Evidenced-based physical therapy does enhance upper limb
recovery, but at 6 months after stroke only 38% of people have some dexterity. Therefore, there is a need
for even better methods of upper limb rehabilitation.
It is known that (1) upper limb recovery is enhanced by physical therapy based on repetitive practice of
everyday tasks and (2) the 3 months immediately after stroke is when recovery is most rapid and there is
most potential for brain recovery. But not everybody responds in the same way to particular forms of
task-specific training. A key influence on therapy response may be the interindivdual differences in how the
stroke affects the brain and, therefore, the neurobiological potential for recovery. Indeed, there is a variety
of neural deficits after stroke seen in different combinations in different people. Therefore, it is important
to have a greater understanding of how these neural deficits influence how people respond to specific
physical therapies.
The trial reported here focused on how different neural deficits early after stroke (1) could predict how an
indivdual may respond to different physical therapies (neural predictive markers) and (2) may change in
response to those therapies (underlying neural mechanisms). Gaining this greater understanding will
progress clinical practice in two ways. First, knowing the neural mechanisms of upper limb recovery will
enable targeting of physical therapy at what needs to change. Second, knowing the neural predictors of
response to specific physical therapies will enhance accuracy of evidenced-based decisions as to what is
the most appropriate therapy for individuals after stroke. These decisions are currently based only on
watching how people move (www.viatherapy.org; accessed 10 May 2018).
The specific forms of physical therapy employed in the trial reported here were functional strength training
(FST) and movement performance therapy (MPT). FST is focused on improving ability to perform everyday
functional tasks. MPT is focused on enhancing quality of movement required for everyday functional tasks.
Such conceptually different physical therapies have been found to be no more or less effective than each
other. However, our earlier trials found variation between people in response to MPT and FST. Therefore,
a comparison of FST and MPT was the context for investigating the neural predictors of response to and
mechanisms of action of specific physical therapies.
Objectives
1. To determine if upper limb motor recovery is enhanced more by FST + conventional physical therapy
(CPT) than by an equal dose of MPT + CPT commenced early after stroke.
2. To identify the similarities and differences in the neural correlates of clinical (observed movement)
improvement in upper limb motor function in response to (1) FST + CPT and (2) MPT + CPT.
3. To determine whether any pretreatment neural characteristics or combination of (1) anatomical location
of infarction, (2) volume of the stroke lesion, (3) residual structural corticocortical connectivity,
(4) residual corticospinal connectivity and (5) brain–muscle functional connectivity [derived from
transcranial magnetic stimulation (TMS)] are sufficiently predictive of upper limb recovery after stroke
to enable physical therapy to be targeted at those people most likely to respond.
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Methods
Design
A randomised, controlled, observer-blind, two-group, multicentre trial with embedded neural measures.
The primary end point was at outcome, which was after the end of the 6-week intervention phase.
The secondary end point was at 6 months after stroke.
Setting and participants
Participants were recruited from three stroke services (Birmingham, Staffordshire and Norfolk) and were
followed up until 6 months after stroke, wherever they were residing. Study criteria (combined inclusion
and exclusion) were people:
l who were between 2 and 60 days after stroke in the territory of the anterior cerebral circulation
when providing informed consent
l aged ≥ 18 years
l who were able, before the index stroke, to use the paretic, contralesional, upper limb to lift and then
drink from a cup
l who were defined as ‘medically stable’, as confirmed by the stroke service medical team
l with enough voluntary muscle contraction in the paretic upper limb to begin to move (score of at least
11 of the 33 points of the Motricity Index pinch section) but unable to complete the Nine-Hole Peg
Test (9HPT) within 50 seconds
l with no obvious spatial neglect (scored 0 or 1 on the Extinction and Inattention subscale of the
National Institutes of Health Stroke Scale)
l who could imitate action with the non-paretic (ipsilesional) upper limb.
Randomisation
Group allocation order was generated before the trial began and was stratified by clinical centre, time
after stroke (up to 30 days and 31–60 days) and ability to use the paretic upper limb as assessed by
the 9HPT (substantial =move one peg or fewer in 50 seconds and moderate =move 2–8 pegs in
50 seconds). An independent telephone randomisation service concealed treatment allocation from
investigators, research therapists and blinded assessors prior to randomisation of a participant.
Interventions
All participants were provided with routine conventional physical therapy (CPT), as deemed appropriate by
the clinical therapists and then either extra MPT or FST in the same dose (amount in minutes).
MPT was prescribed and overseen by a research therapist, direct and non-direct contact, for up to 1.5 hours,
up to 5 days a week for up to 6 weeks (CPT +MPT group). Training in delivering MPT was provided.
FST was prescribed and overseen by a research therapist, direct and non-direct contact, for up to 1.5 hours,
up to 5 days a week (FST + CPT group). Training in delivering FST was provided.
SCIENTIFIC SUMMARY
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Outcome measures
Clinical efficacy measures were made before randomisation (baseline), the working day (± 7 days) after the
6-week intervention ends (outcome) and 6 calendar months (± 14 days) after the index stroke. The primary
outcome measure was the Action Research Arm Test (ARAT) score. Secondary outcome measures were the
Wolf Motor Function Test (WMFT), and the Hand Grip Force and Pinch Grip Force tests.
Neural measures were made within 10 days after the clinical efficacy measures at baseline and at outcome.
These were (1) anatomical location of infarction, (2) volume of the stroke lesion, (3) residual structural
corticocortical connectivity, (4) residual corticospinal connectivity and (5) brain–muscle functional
connectivity (derived from TMS).
Sample size and power
The sample size calculation considered clustered data structure (patients within therapist within treatment
group) and actual ARAT score data from our earlier trial. Assuming an intraclass correlation coefficient
(ICC) of 0.01 in both treatment arms and three centres with a separate therapist for each randomised arm,
a sample size of 99 participants per group had 80% power to detect a clinically important mean difference
of 6.2 in ARAT score change when analysing data using a two-sample t-test with Satterthwaite correction.
This applied a 5% two-sided significance level and allowing for potentially different standard deviations
(SDs) in the CPT +MPT (SD 7.9) and CPT + FST (SD 9.3) groups. To account for clustering in the design a
sample size inflation factor 1 + (m – 1) × ICC was applied (m = cluster size). To allow for an attrition rate of
10% (7% in our previous single-centre trial), 288 participants were recruited (144 per group).
Statistical analyses
In accordance with the intention-to-treat principle, all participants were analysed according to the group to
which they were randomly allocated. The statistical analysis plan was agreed, signed and dated prior to the
database lock and unblinding of the treatment allocations. There was a change to the original analysis
plan from taking account of clustering by therapist to only adjusting for study site, as it was not always
practical for participants to have the same therapist for all their sessions.
Clinical efficacy (objective 1)
The analysis compared the change in the efficacy parameters (baseline and outcome) between the
treatment groups using analysis of covariance (ANCOVA) models adjusted for the baseline value and
randomisation strata (time after stroke, ability to use paretic upper limb, clinical centre). Adjusted least
squares mean difference and 95% confidence intervals are reported. When the outcome distribution
deviated from a normal distribution, a log or other appropriate transformation was applied.
Neural correlates of clinical improvement (objective 2)
Associations between the changes in neural variables were compared with the changes in clinical efficacy
measures (baseline to outcome). Correlation coefficients were calculated for the two treatment groups
separately and for the groups combined.
Predictive neural markers of clinical improvement (objective 3)
For each baseline covariate being investigated as a potential predictive marker of clinical improvement, the
treatment effect (change in ARAT score) was calculated within each level of the subgroup (adjusted as for
the first objective) and an interaction term between randomised treatment and baseline covariate was
included in the model.
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Adverse events
All adverse events (AEs) were recorded from date of randomisation to end of trial. To report serious
adverse events (SAEs) the trial team used the Norwich University Hospital NHS Trust and University of East
Anglia joint standard operating procedure (SOP). The latest version can be found at www.nnuh.nhs.uk/
publication/sop-205-adverse-events/ (accessed 11 May 2018). All SAEs were followed up until a
documented end date and resolution could be provided, or the participant ended the trial.
Results
A total of 5064 stroke survivors were screened for eligibility. Of these stroke survivors, 2929 were excluded
as they did not meet the initial study inclusion criteria. Of the remaining potential participants, 536 declined
participation and, consequently, 481 provided informed consent. Of these, 138 did not meet the eligibility
criteria and a further 55 withdrew informed consent. Therefore, 288 participants were randomised.
Informed consent was provided within 30 days of stroke by 59% of participants and at ≥ 31 days by 41%.
Baseline characteristics were balanced across groups.
Clinical efficacy (objective 1)
The mean age of participants was 72.2 (SD 12.5) years (n = 288) and the mean ARAT score was 25.5
(SD 18.2) (n = 283).
For the 240 participants with a total ARAT score at baseline and outcome, the mean change scores were
9.70 (SD 11.72) for FST + CPT and 7.90 (SD 9.18) for MPT + CPT. The group difference did not reach
statistical significance (p = 0.298).
For the 204 participants with a total ARAT score at baseline and follow-up, the mean change scores were
FST + CPT = 11.10 (SD 14.68) and MPT + CPT = 10.30 (SD 10.74). The group difference did not reach
statistical significance (p = 0.743).
For secondary outcomes, WMFT and Hand Grip Force and Pinch Grip Force tests, there were small
differences between the groups in change from baseline at outcome and follow-up. But these differences
did not reach statistical significance.
Neural correlates of clinical improvement (objective 2)
Analysis was undertaken per neural variable for those people with that variable and a total ARAT score at
both baseline and outcome. Consequently, the number of participants varied across aspects of the analysis.
Correlations between change in total ARAT change scores and baseline neural values ranged from –0.147
(p = 0.385) for whole-sample corticospinal connectivity (n = 37) to 0.199 (p = 0.320) for MPT + CPT resting
motor threshold paretic biceps brachii (n = 27).
Predictive neural markers of clinical improvement (objective 3)
Analysis was undertaken per neural variable for those people with that variable at baseline and a total
ARAT score at both baseline and outcome.
No statistically significant interaction effects were found between baseline neural variables and change in
ARAT score.
Adverse events
There were no differences between groups in the number of AEs.
SCIENTIFIC SUMMARY
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Conclusions
Clinical efficacy (objective 1)
The trial found small differences in the clinical efficacy of upper limb recovery between FST + CPT and
MPT + CPT, but these did not reach statistical significance. Both groups showed increase in ARAT score
(primary outcome measure) above the clinically important change, but variation around the mean change
from baseline scores was substantial in both groups.
Neural correlates of clinical improvement (objective 2)
The neural correlates of change were similar for the two forms of physical therapy.
Objective 3
The trial reported here found that none of the pretreatment neural characteristics of interest predicted
response to either FST + CPT or MPT + CPT.
Implications for health care
The findings of the trial reported here confirm clinical impressions and emerging research evidence of
variation in response to specific therapies among people early after stroke.
Research recommendations
There is still an urgent need for evidence to guide decisions about (1) appropriate prescription of physical
therapy for individuals and (2) the recovery mechanisms at which physical therapy should be targeted.
Trial registration
This trial is registered as ISRCTN 19090862 and National Research Ethics Service reference number 11/EE/0524.
Funding
This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research
Council and National Institute for Health Research partnership.
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Chapter 1 Introduction
The trial reported here focused on a top 10 research priority identified by people who have had a stroke,namely upper limb recovery after stroke.1 Upper limb recovery is a research priority because of the need
to perform everyday tasks such as drinking from a cup, unscrewing the top from a bottle of water and
fastening buttons/zips for independent living. Difficulty with these and other everyday tasks is a frequent
consequence of stroke. Indeed, upper limb neuromuscular weakness (paresis) has been estimated as
occurring in 77% of people after stroke.2 Upper limb recovery is therefore a key target for rehabilitation,
but at 6 months after stroke, only 38% of people have some dexterity.2 ‘Better methods of upper limb
rehabilitation’ are required.1
The socioeconomic impact of residual upper limb disability is high. Indeed, stroke alone produces most of
the adult disability across the globe.3 In England alone, each year around 110,000 people have a stroke
and the estimated annual cost is £9B.4 Most of the cost is in ‘rehabilitation and life after stroke’
(reproduced with permission from the National Audit Office4). The impact is unlikely to lessen because
most people who have a stroke are > 65 years, and the population is ageing. Improving the outcome of
upper limb rehabilitation after stroke is a research priority for the NHS5 and, more widely, across Europe.6
It is known that (1) upper limb recovery is enhanced by the provision of physical therapy based on repetitive
task-specific training,7 and (2) the 3 months immediately after stroke is when recovery is most rapid8 and
there is most potential for central nervous system reorganisation (neuroplasticity).9 However, not everybody
responds in the same way to particular forms of task-specific training. For example, constraint-induced
movement therapy (CIMT) is suitable only for people with at least 10º of voluntary movement of the paretic
thumb and two or more fingers10,11 who are between 3 and 9 months after stroke.12 When used with
people early after stroke, CIMT did not provide better recovery than an equal dose of usual therapy.13 These
and other findings highlight that not everybody has the same set of physiological deficits after stroke,
recovers in the same way or responds to the same form of therapy.14 Therefore, it is important to have a
greater understanding of the mechanisms of recovery and whether a therapy is driving beneficial or
maladaptive neuroplasticity.9–16
Progress towards better methods of upper limb rehabilitation after stroke needs to consider that clinical
phenotype may be insufficient for targeting forms of task-specific therapy to those people most likely to
benefit,17 and that restoring physiological function probably requires the development and application of
rehabilitation therapies that promote activity-driven reorganisation of neural networks spared by the
stroke18 and consideration of the characteristics of the indivdual.19 For example, non-primary cortical motor
regions, including premotor and supplementary motor areas, show adaptation associated with improvement
in movement performance.18,20 This adaptation is most evident in people with greater damage to the
corticospinal system.21,22 In terms of predictive markers, there are experimental, non-trial indications that
baseline, before therapy, brain activity in the primary motor cortex during movement23 and the amount of
damage to descending motor white matter pathways24 at baseline (i.e. before therapy) may be related to
recovery in response to therapy. Accordingly, rehabilitation trials need objective, sensitive neural measures to
understand how a therapy produces benefit (mechanisms) and which people are likely to respond (predictive
markers).14,15,17,18,25 Proof of concept of this approach is provided by investigations into language recovery.26
Gaining this greater understanding will identify the mechanisms that should be targets for therapy and add
information to algorithms designed to aid therapists to provide the most appropriate therapy for individuals27
(www.viatherapy.org).
Realistically, if we are to incorporate mechanism and predictive marker data into accurate models to inform
clinical decision-making then larger sample sizes are clearly required. Embedded in the trial reported here
are objective neuroimaging and neurophysiological measures of participants’ residual motor neural network
before and after a 6-week treatment period.
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The specific forms of physical therapy employed in the trial reported here were functional strength training
(FST) focused on improving ability to perform everyday functional tasks, and movement performance
therapy (MPT) focused on enhancing quality of movement required for everyday functional tasks [called
extra conventional physical therapy (CPT) in our previous early-phase trial].28 FST is based on evidence from
experimental and clinical studies of benefit for people with substantial to moderate paresis early after
stroke.28–34 It forms part of the CPT provided in routine clinical practice. MPT is the component of routine
CPT that is focused on enhancing the quality of the movements required for the performance of everyday
functional tasks.28,35–38 Such conceptually different physical therapies have been found in a meta-analysis to
be no more or less effective than each other.39 However, in both of our early-phase trials we found marked
variation within people in their response to MPT and to FST.28,35 Thus, a comparison of the clinical efficacy
FST and MPT was used in the trial reported here as the context for investigating the predictors of response
to and mechanisms of action to specific physical therapies.
Objectives
The scientific driver for this trial was that detailed understanding of the interaction between the treatment
and each patient’s residual neural function will more likely enable physical therapies to be targeted at
recovery mechanisms in those stroke survivors most likely to respond. The specific objectives were to:
1. determine if upper limb motor recovery is enhanced more by FST+ CPT than an equal dose of MPT + CPT
commenced early after stroke
2. identify the similarities and differences in the neural correlates of clinical improvement in upper limb
motor function in response to (1) FST + CPT and (2) MPT + CPT
3. determine whether or not any pretreatment neural characteristics or combination of (1) anatomical
location of infarction, (2) volume of the stroke lesion, (3) residual structural corticocortical connectivity,
(4) residual corticospinal connectivity and (5) brain–muscle functional connectivity [derived from
Transcranial Magnetic Stimulation (TMS)], are sufficiently predictive of upper limb recovery after stroke
to enable physical therapy to be targeted at those people most likely to respond.
Achieving these objectives before undertaking a Phase III randomised controlled trial (RCT) conforms with
the Medical Research Council (MRC) Framework for Design and Evaluation of Complex Interventions to
Improve Health.40
INTRODUCTION
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Chapter 2 Randomised controlled trial: methods
Design
A randomised, controlled, observer-blind, two-group, multicentre trial. The randomisation order was
generated before the trial began and allocation was via an independent telephone interactive voice
response randomisation service. Clinical efficacy measures were made before randomisation (baseline), the
working day (± 7 days) after the 6-week intervention ended (outcome) and 6 calendar months (± 14 days)
after the index stroke (follow-up). Neural measures were made at baseline and outcome within 10 days
following the clinical efficacy measures. All assessors were blinded at baseline as randomisation had not
yet occurred. At outcome and follow-up all assessors were, where exceptional events did not dictate,
blinded to the randomisation. When at all possible, randomised participants were included in outcome and
follow-up measures. The trial procedure is illustrated in Figure 1. The trial is reported in accordance with
the Consolidated Standards of Reporting Trials (CONSORT) guidelines and covers all the CONSORT
checklist items.
Trial registration
The trial was registered on Current Controlled Trials with the unique identifier ISRCTN19090862
(www.controlled-trials.com). In addition, the protocol was published41 and the study was adopted by the
Baseline
clinical
efficacy
measures
Baseline
explanatory
measures
(within 
10 days)
Randomisation
(immediately
post baseline
clinical efficacy
measures)
Outcome
clinical efficacy
measures 
(day 43 ± 7 days 
post baseline)
Follow-up
clinical
measures 
(6 months 
± 14 days post
stroke)
Outcome
explanatory
measures
(within 
10 days)
MPT + CPT
(up to 1.5 hours
per day, 5 days
per week, for
6 weeks)
FST + CPT
(up to 1.5 hours
per day, 5 days
per week, for
6 weeks)
FIGURE 1 Flow chart to illustrate trial procedure.
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UK Clinical Research Network and, therefore, appeared on the UK Clinical Research Network
Study Portfolio.
Ethics and research governance approval
The Norfolk Research Ethics Service provided ethics approval on 22 February 2012 (reference number
11/EE/0524). All participants provided informed consent.
The trial was outside the scope of the Clinical Trials Directive defined by the Medicines and Healthcare
Products Regulatory Agency as neither trial intervention included provision of a pharmacological compound.
The University of East Anglia (UEA) was the recipient of the funding. UEA together with the University of
Glasgow Clinical Trials Unit [Robertson Centre for Biostatistics (RCB)] and the Norwich Clinical Trials Unit
was responsible for the organisation and running of the trial. UEA had subcontracts with each partner
university that laid out the delegated responsibilities of the partner and funding to be provided. Each
partner university was responsible for procuring suitable management and governance provision with their
local NHS trust centres. All members of the trial team had current good clinical practice (GCP) training.
Those members of the trial who were actively involved in clinical contact with participants but were not
employed by the NHS had either honorary clinical contracts or research passports.
All decisions regarding eligibility for entry, provision of written informed consent, inclusion, exclusion and
attrition were documented as per the MRC Code of Good Practice in Clinical Trials and the CONSORT
guidelines. Relevant trial documentation will be retained for a period of 10 years after the end of data
collection to comply with the GCP regulations and to ensure availability of data for any subsequent
systematic reviews and meta-analyses. The UEA will archive trial documents in a secure facility. The
custodian will be Professor Pomeroy.
Participants
The combined inclusion and exclusion criteria for potential participants were people:
(a) with a clinical diagnosis of stroke in the territory of the anterior cerebral circulation, cortical and/or
subcortical as corroborated through routine clinical imaging
(b) aged ≥ 18 years
(c) who were between 2 and 60 days after stroke when providing informed consent
(d) were able, before the index stroke, to use the paretic, contralesional, upper limb to lift and then drink
from a cup
(e) who were defined as medically stable as confirmed by the stroke service medical team responsible for
the individual’s stroke care
(f) with enough voluntary muscle contraction in the paretic upper limb to score at least 11 of the
33 points on the Motricity Index pinch section42
(g) who were unable to complete the Nine-Hole Peg Test (9HPT) within 50 seconds41
(h) with a score of 0 or 1 on the Extinction and Inattention subscale of the National Institutes of Health
Stroke Scale (no obvious spatial neglect)
(i) who could imitate action with the non-paretic (ipsilesional) upper limb. The research therapist sat
alongside a potential participant to demonstrate five upper limb activities. The potential participant
was asked to watch and then perform the activities. The accuracy of imitation was assessed on the
3-point scale used by Decety: 2 = correctly reproduced action, 1 = incorrectly reproduced action and
0 = not reproduced.43 Those people scoring 8 out of 10 or above were considered as able to imitate
and, therefore, eligible for inclusion in this trial.
RANDOMISED CONTROLLED TRIAL: METHODS
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Settings for recruitment, assessment and treatment
l Birmingham (centre 1).
¢ Moseley Hall Hospital, Birmingham Community Healthcare NHS Trust.
¢ Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust.
¢ University of Birmingham Imaging Centre.
¢ Participants’ own homes.
l Norfolk (centre 2).
¢ Acute Stroke Unit, Norfolk and Norwich University Hospital NHS Trust.
¢ Stroke Rehabilitation Ward, Mulberry Unit, and Early Supported Discharge Team, Norfolk
Community Health and Care NHS Trust.
¢ James Paget University Hospitals.
¢ The Movement Analysis Laboratory at the UEA.
¢ Participants’ own homes.
l North Staffordshire (centre 3).
¢ Haywood Hospital, Staffordshire and Stoke-on-Trent Partnership NHS Trust.
¢ University Hospital of North Midlands NHS Trust.
¢ Participants’ own homes.
Screening and recruitment of participants
Potential participants were screened from the three centres and followed up on the condition that research
governance and ethics approvals were in place for that setting. A two-stage screening process was used
because some study criteria required movement assessment expertise that was not always present in the
Comprehensive Local Research Network (CLRN) screening teams.
Stage 1 of the screening process was conducted by CLRN research nurses in liaison with stroke service
clinical nurses and therapists. They screened for study criteria (a)–(f) as described in Participants (Figure 2).
For some potential participants, the screening happened more than once. This was because medical and
functional characteristics change over time after stroke so if somebody was unsuitable on one occasion it
was possible that they could change and meet the trial criteria later. An individual’s progress was monitored
until eligibility for this trial was clear (Figure 3). At the end of stage 1, informed consent was taken by either
CLRN nurses or research therapists (enrolment). All people screened were categorised as unsuitable, refused
informed consent, or provided informed consent.
People providing informed consent undertook stage two of the screening process with a research therapist
to ascertain concordance with study criteria (g), (h) and (i) (Figure 4). Those people who did not meet all
three of the inclusion criteria were reassessed later if they agreed and the exclusion time limit had not been
met. At the end of stage 2 individuals were categorised as unsuitable for the trial or as a recruited participant.
Randomisation
Before the trial began, the computer-generated randomisation sequence was created by an independent
statistician at the Glasgow Clinical Trials Unit. Participants were allocated to FST + CPT or MPT + CPT in a
1 : 1 ratio, stratified by (1) time after stroke (up to 30 days or 31–60 days); (2) ability to use the paretic upper
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FIGURE 2 Stage 1: initial screening.
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FIGURE 3 Stage 1: participant eligibility pathway. Dark green indicates clinician or research network colleague,
light green indicates research network colleague or researcher, dark blue indicates researcher and light blue
indicates participant.
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FIGURE 4 Stage 2: post-consent suitability assessment. Dark green indicates researcher and light green
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limb as assessed by the 9HPT, moving one peg or less in 50 seconds, or moving 2–8 pegs in 50 seconds;
and (3) clinical centre. An independent telephone randomisation service was used to conceal group allocation
order from investigators, research therapists and blinded assessors prior to the randomisation of a participant.
The telephone randomisation service was contacted by the team member (research therapist or blinded
assessor) immediately after they had completed the baseline measures with a participant.
Sample size and power
The sample size calculation that was used accounted for the expected clustered data structure (patients
within therapist within treatment group).44 This sample size calculation was based on actual ARAT score
data from our previous early-phase trial28 and the expectation that the intraclass correlation coefficient
(ICC) would be somewhat lower than 0.05 for patient outcomes.45 On the assumption of an ICC of 0.01 in
both treatment arms and three centres with a separate therapist for each randomised arm, a sample size
of 99 participants per group would provide 80% power to detect a clinically important mean difference of
6.2 points in ARAT score change for data analysis using a two-sample t-test, with Satterthwaite correction,
applying a 5% two-sided significance level and allowing for potentially different standard deviations (SDs)
in the CPT +MPT (SD 7.9) and CPT + FST (SD 19.3) groups.
To account for clustering in the design (participants within a therapist within randomised treatment at
each study site), a sample size inflation factor 1 + (m – 1) × ICC was applied, where m is the cluster size
and ICC uses SSC software version 1 (Health Services Research Unit, University of Aberdeen, Aberdeen,
UK). On the assumption that recruitment would be distributed evenly across therapists, the sample size
was therefore inflated to 129 evaluable participants per group. To allow for an attrition rate of 10%
(7% in our previous single-centre trial)28 we recruited 144 participants per group. The total sample size
was 288.
Description of interventions
Therapy as usual, conventional physical therapy
All participants continued to receive their usual CPT provided by the clinical therapists. The CPT as delivered
in the centres for the trial combined hands-on techniques emphasising postural alignment and quality of
movement (an aspect of MPT) with goal-orientated task-specific training (an aspect of FST). The content and
amount of CPT delivered to participants was recorded by the clinical therapists each day on a standardised
form (see Appendix 1)46 in accordance with the explanatory manual used in our earlier trials.28,35 The clinical
therapists providing CPT were trained before the trial began. In addition, researchers provided regular
reminders of the rationale for, and importance of, recording CPT and worked with clinicians around using
the treatment schedule focused on queries that arose during the trial. Clinical therapists chose the
CPT that they considered appropriate for participants. Whenever possible, the completed CPT forms were
collected each week by a member of the research team. When not possible, these forms were stored with
the clinical records until completion of the intervention phase and then collected by a member of the
research team.
Trial interventions
The trial interventions were MPT and FST as described in the succeeding subsections.
Research therapists were assigned and trained to provide either FST or MPT. Clinical staff were not told
which research therapist was assigned to provide which trial intervention so that the potential for bias in
the provision of clinician-delivered CPT was minimised. However, this possibility cannot be eliminated
completely as allocation to different types of exercise therapy is not as concealable as, for example,
allocation to an active or placebo pharmaceutical compound.
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Both trial interventions were provided for participants by a research therapist for up to 90 minutes per day,
up to 5 days a week, for up to 6 weeks. It was anticipated that the trial interventions would not be
provided (1) when a participant was unwell, (2) on the day of a trial assessment (e.g. MR scan), (3) when
a participant was unavailable because of holiday or other personal reasons or (4) when there was a UK
public holiday. If a session was missed then the reason for this was recorded. Participants received therapy
both with the therapist physically present (direct contact) and during practice of activities prescribed as
‘homework’ by the research therapist (non-direct contact).
Training in delivering MPT and FST was provided for the research therapists before the first participant was
recruited (see Appendix 2). All research therapists attended this training. If a therapist started during the
trial then their training was completed before their first participant was randomised. In addition, two
training update days were held during the trial for those therapists employed at that point. Through these
update days, the within-trial research therapist networking was maintained and enhanced. This network
enabled research therapists to consult regularly with their peers from different centres providing the same
trial intervention to talk through understandings and practice. The trial manager, Dr Sue Hunter, and
Professor Valerie Pomeroy were also involved in these networking conversations. Fidelity to intervention
protocols was also assessed when Dr Sue Hunter and Professor Valerie Pomeroy made visits at short notice
to accompany research therapists during a treatment session. Notice had to be given because it was
essential to gain agreement from participants concerned. The purpose of training and monitoring was to
minimise potential deviation from intervention protocols and difference between centres.
Trial intervention: movement performance therapy
The hands-on and sensory stimulation components of CPT that focus on restoring movement quality
(i.e. efficient, smooth, timely, co-ordinated movement with normal alignment or symmetry of body structures
prior to retraining functional movement) can be termed MPT.36 MPT is ‘therapist dependent’, particularly when
there is limited voluntary muscle activation; the therapist monitors and provides intrinsic feedback on movement
performance through skilled observation, handling and facilitation techniques. Therapist-led hands-on guidance
and feedback assists practice of functional tasks. Trial MPT emphasised interventions provided by a therapist
using facilitation and guiding movement (therapist dependent) to provide sensory input to optimise joint
alignment in preparation for voluntary movement (see Appendix 3). Some iterative practice of functional
tasks was included but without systematic progression in resistance to movement or repetition.
Trial intervention: functional strength training
Functional strength training was provided according to a treatment schedule consisting of standardised
therapy activities.47 An online supplement to the published paper provides full details47 in accordance with
the TIDieR (Template for Intervention Description and Replication) guidelines.48 In summary, FST is repetitive
progressive resistive exercise during goal-directed functional activity, with the therapist providing verbal
prompting and feedback. Hands-on intervention is not provided other than that required to maintain safety
(e.g. prevent a fall). FST focuses on improving the power of shoulder/elbow muscles for appropriate placing of
the hand for the task being practised, the production of appropriate force in the arm and hand muscles to
achieve the specific grasp, and manipulation of everyday objects. Initially, the resistance level is the maximum
load that permits five repetitions of the task being practised. Systematic progression uses repetition and
increased resistance. Content of FST is divided into (1) specific movements for muscle groups (e.g. emphasis
on elbow flexion/extension), (2) upper limb gross movement patterns underlying functional activity (e.g.
shoulder flexion/external rotation and elbow extension to reach forward), (3) hand reaching/retrieval activity
(e.g. reaching to grasp something on a shelf while seated), (4) hand grip activities, (5) hand manipulation
involving entire everyday movements and (6) using objects such as screw top canisters, pegs, food items (e.g.
bag of dried pasta), mugs and pens. These activities are extended into more complex everyday activities such
as using the paretic upper limb to place different food items into a shopping bag and then lift the bag onto a
shelf, and open a bottle and drink from it and pour tea from a pot. The therapist provides feedback and
instructions that encourage an external focus of attention (e.g. whether or not the teapot has been lifted off
the table) rather than focusing on the arm/hand (e.g. amount of shoulder movement when lifting the teapot)
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and informative verbal feedback on performance on at least 50%, but less than 100%, of attempts to
encourage self-evaluation for motor learning.
Measurement battery
Clinical efficacy measures: objective 1
For the clinical efficacy measures (objective 1) participants were seated in an upright chair, except for
some items of the Wolf Motor Function Test (WMFT), which allows for a posture in which knees, hips and
ankles are maintained at 90°. A table was available so that, when appropriate for the measurements, the
forearms were supported on the table with elbows directly below the glenohumeral joint at the start of an
item of the WMFT. Measures pertain to the contralesional upper limb (paretic).
The primary outcome measure was:
l The Action Research Arm Test (ARAT), which has four subsections (grasp, grip, pinch and gross
movements). Within each subsection are three to six items scored from 0 (unable) to 3 (normal
performance), giving a total possible score of 57.49 The ARAT is a measure of the primary focus of
both interventions (i.e. improved upper limb function).
The secondary outcome measures were:
l The WMFT, which is a valid and reliable assessment with 15 items designed for use with stroke
survivors and is complementary to the ARAT. It measures quality of movement during 15 functional
tasks including both simple actions (e.g. placing forearm on table) and complex tasks (e.g. turning key
in a lock).50,51
l Hand Grip and Pinch Grip Force tests using a myometer held securely on a stable surface. The upper
limb position for both pinch and grip force was standardised52 and the myometer was set to ‘zero’
after the subject was positioned with their hand/digits around the bars, ‘at rest’. Force values were
obtained during three trials for which participants were instructed to ‘squeeze as hard as you can’.
The maximum value was used for data analysis.
Neural measures: objectives 2 and 3
Participants were studied twice: at baseline and at outcome (see Design). The trial team had systems in
place to maintain consistency and data quality across sites and to treat multicentre data appropriately.
Full training was given to all trial centre teams.
Once testing began, data from all sites were promptly sent to the University of Oxford team for rigorous
quality control prior to processing to extract relevant values. Quality control assessments included manual
checks (e.g. subject motion) and automated checks (e.g. signal-to-noise ratio, motion correction
parameters and range checks).
To maximise recruitment to and minimise attrition from neural measures, we provided participants with
full explanations and opportunities to ask questions and plenty of time to be made comfortable and to
practice the tasks.
The neural measures were:
1. The anatomical overlap of the stroke lesion with the corticospinal tract [Montreal Neurological
Institute (MNI) CST – yes/no]. This variable identifies whether or not the lesion overlaps with a mask
approximating the CST. The CST mask was defined using tractography in a group of control brains in
standard space to track between motor cortex and medullary pyramids. The lesion was delineated
manually on each patient’s T1-weighted 1 × 1 × 1 mm brain image using FSL view, an image viewing
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tool available within the Oxford Centre for Functional Magnetic Resonance Imaging of the Brain’s
(FMRIB) Software Library (FSL). Overlap between the lesion volume and the CST was determined by
overlaying the lesion mask with the CST mask.
2. The volume of the stroke lesion (lesion volume mm3). This variable was determined by calculating the
volume of the manually defined stroke mask described for (1).
3. Corticocortical anatomical connectivity as per fractional anisotropy (FA) from corpus callosum midline
(FA MNI corpus callosum midline – range = 0–1). Diffusion tensor imaging data were first corrected for
head motion and eddy current using tools from FSL. A diffusion tensor model was then fitted to the
pre-processed data to calculate voxel-wise values of FA. Mean FA from within a standard space region
of interest, incorporating the whole corpus callosum on a midline brain slice, was calculated.
4. Corticospinal anatomical integrity as per asymmetry of CST FA (ipsilesional-to-contralesional ratio MNI
CST – range = –1 to 1). Regions of interest on a single slice at the level of the internal capsule were
created to provide masks estimating the location of the CST. Mean FA from within these masks was
calculated. A ratio of ipsilesional-to-contralesional values was calculated.
5. Corticospinal functional connectivity as per presence or absence of a resting motor-evoked potential
(MEP) for biceps brachii muscle in paretic upper limb (yes/no). Single pulses of TMS using a standard
70 mm figure-of-eight coil were given over the hand/arm area of primary motor cortex of the
ipsilesional hemisphere and then the contralesional hemisphere. MEP data were recorded and
processed using electromyography data collection software. Resting motor threshold (RMT) was defined
as the stimulator output that produced > 50 µV in 5 out of 10 trials.53
6. Corticospinal functional connectivity as per presence or absence of a resting MEP for the extensor carpi
radialis muscle in the paretic (contralesional) upper limb (yes/no). Data were processed as for (5).
7. The RMT in paretic biceps brachii (pBB) when MEP was present (percentage). Value extracted was the
lowest percentage output of the stimulator at which a MEP was present.
8. The RMT in paretic extensor carpi radialis when MEP was present (percentage). The value extracted was
the lowest percentage output of the stimulator at which a MEP was present.
Adverse reactions and adverse events
Participation in FST and MPT is considered low risk for adverse events (AEs). However, there is a small
possibility that either therapy could be associated with an overuse syndrome, expressed as experience
of pain or fatigue. These were therefore classified as potential adverse reactions as follows:
l Pain was considered an adverse reaction if (1) a participant reported onset or increase of paretic upper
limb pain (verbally or behaviourally), (2) the pain was sustained over four consecutive therapy sessions
and (3) the clinical team were unable to account for this in any other way than involvement in the trial.
If pain occurred then the research therapist adjusted the trial therapy as appropriate or, if indicated,
stopped it on either a permanent or temporary basis. The date of the adverse reaction was recorded as
the date of the fourth therapy session.
l Fatigue was considered to have occurred if (1) a participant demonstrated a decrease of two levels in
the Motricity Index upper limb score on two consecutive therapy sessions and (2) the clinical team
could not account for this in any other way than involvement in the trial. This was addressed by the
therapist adjusting the trial therapy as appropriate or, if indicated, stopping the trial therapy on either
a permanent or temporary basis. The date of the adverse reaction was recorded as the date of the
second therapy session.
To report serious adverse events (SAEs), the trial team used the Norfolk and Norwich University Hospital
and UEA joint standard operating procedure (SOP). The latest version can be found www.nnuh.nhs.uk/
Dept.asp?ID%20=%20681 (see SOP 205). All SAEs were assessed by the local principal investigator,
countersigned by the chief investigator, reported to the sponsor and reported to the Data Monitoring
and Ethics Committee (DMEC) and Trial Steering Committee (TSC). All SAEs were followed up until a
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documented end date and resolution could be provided, or the participant ended the trial. Participants
were considered to have reached the end of the trial when the first of the following occurred:
l completion of assessment at 6 months after stroke
l withdrawal of consent
l SAE resulting in withdrawal of participant or death
l loss to follow-up.
If a SAE was still ongoing at the time a participant reached a trial end point, their trial end date was also
used to record their SAE end data.
Statistical analysis
The statistical analysis plan (SAP) was agreed, signed and dated prior to the database lock and unblinding
of the treatment allocations (see Appendix 4).
There was a change to the original analysis plan from taking account of clustering by therapist to only
adjusting for the study site. The change was made because, for practical reasons, the participants were not
clustered within the same therapist for all their sessions.
Clinical efficacy (objective 1)
To address objective 1 the primary analysis compared the change in the efficacy parameters (baseline and
outcome) between the treatment groups. Change in the efficacy parameters (ARAT, WMFT, and Hand
Grip Force and Pinch Grip Force tests) at outcome were analysed using analysis of covariance (ANCOVA)
models adjusted for the baseline value and randomisation strata (time after stroke, ability to use paretic
upper limb, clinical centre). Adjusted least squares mean difference and 95% confidence intervals (CIs)
were reported. When the outcome distribution deviated from a normal distribution, a log or other
appropriate transformation was applied.
Neural correlates of clinical improvement (objective 2)
To answer the second objective, associations between the changes in neural variables were compared with
the changes in clinical efficacy measures (baseline to outcome). Correlation coefficients were calculated for
the two treatment groups separately and for the groups combined.
Predictive neural markers of clinical improvement (objective 3)
The third objective was answered through subgroup analysis of the change in ARAT score at outcome.
For each baseline covariate being investigated as a potential predictive marker of clinical improvement,
the treatment effect was calculated within each level of the subgroup (adjusted as for the first objective)
and an interaction term between randomised treatment and baseline covariate was included in the model.
Trial management
Data collection
All data were collected in accordance with trial operating procedures. These were developed to the
standards required in the SOPs of the Norwich Clinical Trial Unit.
Case report forms (CRFs) were developed to enable capture of primary and secondary outcome data at the
time points of baseline, outcome and follow-up. In addition, the CRFs recorded demographic information
such as sex and type of stroke. Throughout the trial, the completed CRFs were secured in a locked filing
cabinet in a research office in the Moseley Hall Hospital (Birmingham), the Queen’s Building at the UEA
(Norfolk), or the Haywood Hospital (North Staffordshire). Once the follow-up phase of the trial was
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completed, all CRFs were moved securely to the UEA for final data query resolution, in preparation for the
final database lock. All CRFs were then securely stored and archived at the UEA.
Data entry and quality assurance
The study database was set up and managed by the Data Management Team at Glasgow Clinical Trials
Unit. The data management plan is included as Appendix 5. Data management included:
l design and specification of the database and data entry system
l real-time validation of data entry for data types and ranges
l provision of a double data entry and checking system at the end of the study
l import of data
l data queries for validation at end of study
l database lock
l data set extraction for analysis.
Procedures were developed, implemented and monitored to maintain blinding and limit access of
members of the research team to data throughout the trial. Data were sent to the RCB for entry and
quality control in a secure standardised manner in keeping with the Data Management Plan produced by
the RCB (see Appendix 5). The RCB was responsible for accumulating, reviewing and reporting on data
from several primary and secondary sources.
Primary data sources were from paper copies of study CRFs completed at study site.
Secondary data sources were from (1) database amendment requests and (2) responses to data queries.
External data sources included the results of the TMS and magnetic resonance imaging (MRI)
tests/procedures.
Trial Steering Committee
A TSC was convened to provide overall supervision and ensure good conduct of the trial (e.g. adherence
to the Declaration of Helsinki and good practice in user involvement). This was undertaken by nominating
potential members to the Efficacy and Mechanism Evaluation (EME) programme board, which then
appointed people to the TSC. Members of the TSC were:
l Professor Anne Forster (independent chairperson)
l Professor Christopher Weir (collaborator, statistician and methodologist)
l Dr Sue Hunter (collaborator, principal investigator)
l Professor Jon Marsden (independent member)
l Professor John Rothwell (collaborator, TMS lead)
l Professor Valerie Pomeroy (chief investigator)
l Dr Ailie Turton (independent member)
l Ms Emma Costello (clinical research administrator)
l Mr Nick Leavey (clinical trial manager).
The TSC met on 22 November 2012, 23 May 2013, 27 August 2013, 11 December 2013, 6 February
2014, 3 July 2014, 27 February 2015, 11 April 2016 [a full meeting was not convened on request of
independent chairperson (AF); however, an up-to-date trial progress report was distributed to the TSC and
comments were subsequently shared and responded to by e-mail)] and 5 December 2016 (a final TSC
meeting to review the final Robertson Centre Report and the current draft monograph).
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Data Monitoring and Ethics Committee
The DMEC reported directly to the chair of the TSC. Members of the DMEC appointed by the EME
programme were:
l Professor Sally Singh (independent chairperson)
l Professor Gert Kwakkel (independent member)
l Dr Martyn Lewis (independent member)
l Professor Valerie Pomeroy (chief investigator)
l Dr Andrew Walker (until 31 December 2014) (clinical trial manager)
l Nick Leavey (from 3 September 2014) (clinical trial manager).
The DMEC met on 16 July 2013, 29 January 2014, 16 July 2014, 2 February 2015, 2 September 2015 and
25 November 2016.
Public and Patient Involvement
At the beginning of the trial, the initial trial manager and Professor Pomeroy attempted to secure a Patient
and Public Involvement (PPI) representative through the Patient and Public Involvement in Research (PPIRes)54
group. An early version of the protocol for the grant application was reviewed by PPIRes. Unfortunately,
however, no one was identified by PPIRes to be the PPI representative for this trial.
Nonetheless, PPI has still taken various forms throughout the trial. From the outset, the trial featured at
meetings of the Norfolk Community Health and Care NHS Trust patient and carer groups, in Norwich.
The trial team therefore benefited from PPI comments and suggestions on a range of elements, particularly
the development of participant information resources.
Further PPI was also explored by Dr Andrew Walker via a contact provided by the EME programme
manager. This did not lead to further PPI. Therefore, a replacement PPI representative was not identified at
this point in the trial.
As outlined in the progress report submitted on 1 April 2015, a PPI representative was identified from
Headway Suffolk. The person identified was Helen Fairweather, the chief executive officer of Headway
Suffolk, who kindly agreed to be a member of the TSC. Since April 2015, Helen has been invited to all
TSC meetings and sent copies of the agendas and subsequent minutes and associated documents.
A participant thank-you event was held at the Norwich Community Hospital on 3 May 2016. The event
was to celebrate the trial achieving its 288-participant recruitment target. Over 50 local participants
attended, who were provided with a verbal report on the remaining ongoing trial activity and plans for
dissemination of the trial results. All were appreciative of their involvement in the trial and comments were
received in approval of the dissemination plan.
During the trial, and following a substantial amendment (eighth amendment), three editions of a FAST
INdICATE participant newsletter were distributed to trial participants to keep them updated on trial
progress and its planned dissemination.
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Chapter 3 Results: clinical efficacy
Objective addressed
To determine if upper limb motor recovery is enhanced more by FST + CPT than an equal dose of
MPT + CPT commenced early after stroke.
Dates of recruitment and follow-up periods
Screening for potential participants started on 1 April 2012 and ended on 25 January 2016. The first
participant was randomised on 17 October 2012 and the last participant was randomised on 29 January
2016. The last follow-up assessment, at 6 months after stroke, was 6 July 2016.
Participant characteristics
The characteristics of participants are detailed in Table 1. In summary, the mean age (SD) of participants in
this trial was 72.2 (12.5) years. The sex distribution was 64.6% male and 35.4% female. Informed consent
was given within 30 days of stroke by 59% of participants and at ≥ 31 days by 41%. All participants had
been diagnosed with stroke in the territory of the anterior cerebral circulation. The stroke was caused by a
haemorrhage for 8.7% of participants and by ischaemia for 91.3%. The right-hand side of the body was
more affected by the stroke than the left-hand side for 42% of participants.
Flow of participants through the trial
The CONSORT flow chart for this trial in respect to the primary outcome (ARAT score) is provided in Figure 5.
In summary, a total of 5064 stroke survivors were screened for eligibility for this trial. Of these, 2929 (58%)
were excluded because they did not meet the initial study inclusion criteria, with a further 872 (17%)
excluded for additional reasons, such as being outside the trial catchment area or having severe cognitive
and/or language impairment. This left 1263 identifiable eligible people; however, 536 (42%) of these
people declined to talk to the research team. The remaining 481 (38%) provided informed consent and
undertook the trial suitability screening assessment; of those, 138 (29%) did not meet the eligibility criteria
and a further 55 (11%) either withdrew consent or otherwise were not randomised. The remaining 288
were recruited as participants and randomised into the trial. Consequently, 288 participants undertook the
baseline assessments and were subsequently allocated randomly to the MPT group (n = 143) or the FST
group (n = 145).
At the primary end point of the outcome (at the end of the 6-week intervention phase), 245 (85.1%)
participants undertook the primary measure (ARAT score), of whom 119 had been allocated to MPT + CPT
and 126 to FST + CPT. Attrition reasons were:
l withdrew as a result of a SAE or AE (MPT + CPT, n = 5; FST + CPT, n = 5)
l unwilling to continue (MPT + CPT, n = 6; FST + CPT, n = 6)
l withdrew consent (MPT + CPT, n = 4; FST + CPT, n = 2)
l lost to outcome/other (MPT + CPT, n = 5 FST + CPT, n = 3)
l did not attend for assessment, but remained in trial (MPT + CPT, n = 4; FST + CPT, n = 3).
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At 6 months after stroke, the follow-up time point, 208 (72.2%) participants undertook the primary
measure (ARAT score), of whom 104 were allocated to MPT + CPT and 104 to FST + CPT. Attrition at the
follow-up point had occurred for the following reasons:
l withdrew as a result of a SAE or AE (MPT + CPT, n = 15; FST + CPT, n = 8)
l unwilling to continue (MPT + CPT, n = 13; FST + CPT, n = 11)
l withdrew consent (MPT + CPT, n = 4; FST + CPT, n = 3)
l investigator withdrawal (MPT + CPT, n = 0; FST + CPT, n = 1)
l lost to outcome/other (MPT + CPT, n = 7; FST + CPT, n = 18).
Adverse reactions, adverse events and serious adverse events
No SAEs met the criteria for reporting to the National Research Ethics Service. All SAEs were reviewed by
the DMEC. Only four participants experienced an adverse reaction of pain or fatigue during the
intervention phase (Table 2).
TABLE 1 Participant characteristics, by treatment group and overall, at baseline
Characteristic
Treatment group
All (N= 288)FST+ CPT (N= 145) MPT+ CPT (N= 143)
Age (years), mean (SD) 71.9 (12.7) 72.4 (12.3) 72.2 (12.5)
Sex, n (%)
Male 96 (66.2) 90 (62.9) 186 (64.6)
Female 49 (33.8) 53 (37.1) 102 (35.4)
Type of stroke, n (%)
Ischaemic 131 (90.3) 132 (92.3) 263 (91.3)
Haemorrhagic 14 (9.7) 11 (7.7) 25 (8.7)
Side of brain lesion, n (%)
Left 63 (43.5) 58 (40.6) 121 (42.0)
Right 82 (56.5) 85 (59.4) 167 (58.0)
9HPT at consent, n (%)
≤ 1 peg 91 (62.8) 90 (63.0) 181 (62.9)
2–8 pegs 54 (37.2) 53 (37.1) 107 (37.2)
Days after stroke at consent, n (%)
≤ 30 days 86 (59.3) 84 (58.7) 170 (59.0)
≥ 31 days 59 (40.7) 59 (41.3) 118 (41.0)
ARAT total score – paretic, mean score (SD)a 24.7 (18.9) 26.2 (17.4) 25.5 (18.2)
WMFT – performance, mean score (SD)b 36.4 (20.25) 37.6 (17.1) 37.0 (18.8)
Grip force (kg), mean score (SD)c 7.6 (8.7) 6.9 (8.1) 7.2 (8.4)
Pinch force (kg), mean score (SD)d 2.2 (2.2) 1.9 (2.3) 2.1 (2.2)
a Number of data sets available for analysis were: FST + CPT = 144; MPT + CPT= 139; and All = 283.
b Number of data sets available for analysis were: FST + CPT = 136; MPT + CPT= 129; and All = 265.
c Number of data sets available for analysis were: FST + CPT = 141; MPT + CPT= 139; and All = 280.
d Number of data sets available for analysis were: FST + CPT = 131; MPT + CPT= 133; and All = 264.
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Randomised
(n = 288)
Assessed for eligibility
by research team
(n = 481)
Given information about
trial by research team
(n = 726)
Clinical team asked for
patient’s permission to talk
to research team
(n = 1263)
Assessed for eligibility
by clinical team
(n = 5064)
Allocated to intervention MPT + CPT
(n = 143)
Baseline assessment completed
(n = 143)
         Primary outcome completed 
  (n = 119)
                      Follow-up assessment completed 
                    (n = 104)
      
• Excluded from analysis,a n = 4
Allocated to intervention FST + CPT
(n = 145)
Baseline assessment completed
(n = 145)
                Primary outcome completed 
                                                  (n = 126)
        Follow-up assessments completed 
                         (n = 104)
        Not meeting inclusion criteria 
    (n = 2929)
   •  Aged < 18 years, n = 6
   •  Not anterior stroke, n = 1333
   •  Unable to lift cup before stroke, n = 33 (missing n = 30)
   •  Not medically stable, n = 1103
   •  > 60 days post stroke, n = 299
   •  Less than minimum UL function, n = 125
  
 
   •  Declined to talk to research team, n = 536
   •  Research team unavailable, n = 1
 
   •  Declined informed consent, n = 207
   •  Unable to give informed consent, n = 1
        Not meeting eligibility criteria 
                                         (n = 138)
   •  Less than minimum UL function, n = 12
   •  Less than maximum UL function, n = 114
   •  Unable to imitate, n = 7
   •  Severe neglect, n = 5
  
Outcome 
(n = 118)
• Withdrawn as a result of a SAE, n = 7
• Withdrawn as a result of an AE, n = 1
• Unwilling to continue, n = 11
• Withdrew consent, n = 3
• Investigator withdrawal, n = 1
• Lost to follow-up/other, n = 18
• Withdrawn as a result of a SAE, n = 14
• Withdrawn as a result of an AE, n = 1
• Unwilling to continue, n = 13
• Withdrew consent, n = 4
• Investigator withdrawal, n = 0
• Lost to follow-up/other, n = 7
• Excluded from analysis,a n = 1
Follow-up
 (n = 103)
• Excluded from analysis,a n = 1
Baseline 
(n = 139)
Baseline 
(n = 144)
• Excluded from analysis,a n = 1
Outcome 
(n = 126)
Follow-up 
(n = 104)
• Withdrawn as a result of a SAE, n = 5
• Withdrawn as a result of an AE, n = 0
• Unwilling to continue, n = 6
• Withdrew consent, n = 4
• Investigator withdrawal, n = 0
• Lost to outcome/other, n = 5
• Did not attend assessment but remained in trial, n = 4
• Withdrawn as a result of a SAE, n = 4
• Withdrawn as a result of an AE, n = 1
• Unwilling to continue, n = 6
• Withdrew consent, n = 2
• Investigator withdrawal, n = 0
• Lost to outcome/other, n = 3
• Did not attend assessment but remained in trial, n = 3
   •  Out of area, n = 306
   •  Severe cognitive/language impairment, n = 294
   •  Patient or clinical team unavailable, n = 221
   •  Enrolled in other trial, n = 35
   •  Recruitment target already met, n = 16
Additional reasons given 
(n = 872)
Withdrew consent, n = 38
Patient unable to attend post-consent screen/baseline, n = 8
Deceased, n = 1
Not randomised as a result of co-enrolment, n = 2
Research team unavailable, n = 3
Post-consent exclusion time limit reached, n = 2
Ineligible as found to have a posterior circulation stroke, n = 1
FIGURE 5 All centres: CONSORT 2010 flow diagram. a, Data are excluded from analysis if missing items prevent the
ARAT total score from being calculated. UL, upper limb.
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Adverse events, related AEs, SAEs and unexpected AEs during the intervention phase are detailed in
Tables 3–6. No clinically important differences are detectable between the FST + CPT and MPT + CPT groups.
Those AEs, related AEs, SAEs and unexpected AEs that occurred during the follow-up phase are detailed in
Tables 7–10. No clinically important differences are detectable between the FST + CPT and MPT + CPT groups.
TABLE 2 Number of participants experiencing an adverse reaction during the treatment phase by treatment group
and overall
Adverse reaction
Treatment group, n (%)
All (N= 288), n (%)FST+ CPT (N= 145) MPT+ CPT (N= 143)
Any adverse reaction of pain 1 (0.69) 1 (0.70) 2 (0.69)
Any adverse reaction of fatigue 3 (2.07) 1 (0.70) 4 (1.39)
TABLE 3 Number of participants experiencing AEs during the intervention phase, by treatment group
(one participant may have experienced more than one event)
Adverse event
Treatment group, n (%)
FST+ CPT (N= 145) MPT+ CPT (N= 143)
Any event 56 (38.62) 59 (41.26)
Injury, poisoning and procedural complications 18 (12.41) 19 (13.29)
Infections and infestations 17 (11.72) 7 (4.90)
Musculoskeletal and connective tissue disorders 11 (7.59) 11 (7.69)
General disorders and administration site conditions 11 (7.59) 8 (5.59)
Nervous system disorders 8 (5.52) 8 (5.59)
Gastrointestinal disorders 4 (2.76) 6 (4.20)
Vascular disorders 1 (0.69) 8 (5.59)
Psychiatric disorders 5 (3.45) 1 (0.70)
Respiratory, thoracic and mediastinal disorders 1 (0.69) 4 (2.80)
Cardiac disorders 1 (0.69) 3 (2.10)
Renal and urinary disorders 2 (1.38) 1 (0.70)
Eye disorders 0 (0.00) 2 (1.40)
Immune system disorders 1 (0.69) 1 (0.70)
Investigations 0 (0.00) 2 (1.40)
Ear and labyrinth disorders 1 (0.69) 0 (0.00)
Metabolism and nutrition disorders 0 (0.00) 1 (0.70)
Neoplasms benign, malignant and unspecified 0 (0.00) 1 (0.70)
Social circumstances 1 (0.69) 0 (0.00)
Surgical and medical procedures 0 (0.00) 1 (0.70)
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TABLE 4 Number of participants experiencing a related AE during the intervention phase, by treatment group
Related AE
Treatment group, n (%)
FST+ CPT (N= 145) MPT+ CPT (N= 143)
Any event 5 (4.45) 9 (6.29)
Injury, poisoning and procedural complications 1 (0.69) 1 (0.70)
Musculoskeletal and connective tissue disorders 4 (2.76) 3 (2.10)
General disorders and administration site condition 1 (0.69) 2 (1.40)
Nervous system disorders 0 (0.00) 2 (1.40)
Eye disorders 0 (0.00) 1 (0.70)
Metabolism and nutrition disorders 0 (0.00) 1 (0.70)
TABLE 5 Number of participants experiencing a SAE during the intervention phase, by treatment group
SAE
Treatment group, n (%)
FST+ CPT (N= 145) MPT+ CPT (N= 143)
Any event 17 (11.72) 11 (7.69)
Injury, poisoning and procedural complications 1 (0.69) 2 (1.40)
Infections and infestations 6 (4.14) 0 (0.00)
Musculoskeletal and connective tissue disorders 1 (0.69) 0 (0.00)
General disorders and administration site conditions 4 (2.76) 0 (0.00)
Nervous system disorders 4 (2.76) 2 (1.40)
Gastrointestinal disorders 1 (0.69) 0 (0.00)
Psychiatric disorders 1 (0.69) 1 (0.70)
Respiratory, thoracic and mediastinal disorders 0 (0.00) 1 (0.70)
Cardiac disorders 1 (0.69) 3 (2.10)
Immune system disorders 1 (0.69) 0 (0.00)
Neoplasms benign, malignant and unspecified 0 (0.00) 1 (0.70)
Surgical and medical procedures 0 (0.00) 1 (0.70)
TABLE 6 Number of participants experiencing an unexpected SAE during the intervention phase, by treatment
group
Unexpected SAE
Treatment group, n (%)
FST+ CPT (N= 145) MPT+ CPT (N= 143)
Any event 9 (6.21) 4 (2.80)
Injury, poisoning and procedural complications 0 (0.00) 1 (0.70)
Infections and infestations 4 (2.76) 0 (0.00)
General disorders and administration site condition 1 (0.69) 0 (0.00)
Nervous system disorders 2 (1.38) 0 (0.00)
Gastrointestinal disorders 1 (0.69) 0 (0.00)
Psychiatric disorders 0 (0.00) 1 (0.70)
Respiratory, thoracic and mediastinal disorders 0 (0.00) 1 (0.70)
Cardiac disorders 0 (0.00) 1 (0.70)
Immune system disorders 1 (0.69) 0 (0.00)
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TABLE 7 Number of participants experiencing an AE during the follow-up phase, by treatment group
AE
Treatment group, n (%)
FST+ CPT (N= 145) MPT+ CPT (N= 143)
Any event 22 (15.17) 35 (24.48)
Injury, poisoning and procedural complications 8 (5.52) 10 (6.99)
Infections and infestations 7 (4.83) 6 (4.20)
Skin and subcutaneous tissue disorders 1 (0.69) 4 (2.80)
General disorders and administration site conditions 2 (1.38) 5 (3.50)
Nervous system disorders 3 (2.07) 7 (4.90)
Gastrointestinal disorders 1 (0.69) 3 (2.10)
Vascular disorders 0 (0.00) 1 (0.70)
Psychiatric disorders 2 (1.38) 1 (0.70)
Respiratory, thoracic and mediastinal disorders 0 (0.00) 3 (2.10)
Renal and urinary disorders 1 (0.69) 0 (0.00)
Eye disorders 0 (0.00) 1 (0.70)
Neoplasms benign, malignant and unspecified 0 (0.00) 1 (0.70)
Musculoskeletal and connective tissue disorders 1 (0.69) 1 (0.70)
Surgical and medical procedures 3 (2.07) 2 (1.40)
TABLE 8 Number of participants experiencing a related AE during the follow-up phase, by treatment group
Related AE
Treatment group, n (%)
FST+ CPT (N= 145) MPT+ CPT (N= 143)
Any event 3 (2.07) 0 (0.00)
Musculoskeletal and connective tissue disorders 1 (0.69) 0 (0.00)
General disorders and administration site condition 1 (0.69) 0 (0.00)
Nervous system disorders 1 (0.69) 0 (0.00)
TABLE 9 Number of participants experiencing a SAE during the follow-up phase, by treatment group
SAE
Treatment group, n (%)
FST+ CPT (N= 145) MPT+ CPT (N= 143)
Any event 5 (3.45) 13 (9.09)
Injury, poisoning and procedural complications 1 (0.69) 2 (1.40)
General disorders and administration site conditions 1 (0.69) 1 (0.70)
Nervous system disorders 1 (0.69) 6 (4.20)
Gastrointestinal disorders 0 (0.00) 1 (0.70)
Psychiatric disorders 1 (0.69) 2 (1.40)
Respiratory, thoracic and mediastinal disorders 0 (0.00) 2 (1.40)
Renal and urinary disorders 1 (0.69) 0 (0.00)
Neoplasms benign, malignant and unspecified 0 (0.00) 1 (0.70)
Surgical and medical procedures 1 (0.69) 0 (0.00)
RESULTS: CLINICAL EFFICACY
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Primary clinical efficacy analysis
The primary outcome measure was ARAT score. There were 126 participants for the FST + CPT group and
114 for the MPT + CPT group with data at both baseline and outcome (Table 11). At follow-up, the
number of participants with data at baseline had reduced to 104 for the FST + CPT group and to 100 for
the MPT + CPT group (Table 12). Both groups showed improvement (mean and SD) from baseline at
outcome [FST + CPT = 9.70 (SD 11.72) and MPT + CPT = 7.90 (SD 9.18)], but there was little difference
between the groups and this did not reach statistical significance (p = 0.298). Further improvements were
evident at follow-up with mean (SD) changes from baseline of 11.10 (SD 14.68) for the FST + CPT group
and 10.3 (SD 10.74) for the MPT+ CPT group. Again, this difference was small and did not reach statistical
significance (p = 0.743).
Secondary clinical efficacy analysis
Secondary clinical efficacy outcome measures (Tables 13–18) showed a similar pattern to the ARAT scores
(primary outcome) in terms of their mean improvements. SDs indicated more variability in response for grip
and pinch force. Differences between groups were small and did not reach statistical significance.
TABLE 10 Number of participants experiencing an unexpected SAE during the follow-up phase, by treatment group
Unexpected SAE
Treatment group, n (%)
FST+ CPT (N= 145) MPT+ CPT (N= 143)
Any event 2 (1.38) 7 (4.90)
Injury, poisoning and procedural complications 0 (0.00) 1 (0.70)
Nervous system disorders 0 (0.00) 2 (1.40)
Gastrointestinal disorders 0 (0.00) 1 (0.70)
Psychiatric disorders 0 (0.00) 2 (1.40)
Respiratory, thoracic and mediastinal disorders 0 (0.00) 2 (1.40)
Renal and urinary disorders 1 (0.69) 0 (0.00)
Neoplasms benign, malignant and unspecified 0 (0.00) 1 (0.70)
Surgical and medical procedures 1 (0.69) 0 (0.00)
TABLE 11 Change from baseline to outcome for ARAT score, paretic upper limb for participants with data at both
time points
Comparison
Treatment
group
Number of
participantsa
Mean (SD) Mean (95% CI)
Baseline Outcome Change Least squares
Least squares
difference and
p-value of change
between group
Change at
outcome
FST + CPT 126 24.40
(18.45)
34.10
(17.81)
9.70
(11.72)
9.80
(7.87 to 11.73)
1.35
(–1.20 to 3.90);
p= 0.298
MPT + CPT 114 26.50
(17.78)
34.40
(18.68)
7.90 (9.18) 8.45
(6.41 to 10.49)
a Number of participants with data at both baseline and outcome.
DOI: 10.3310/eme05030 EFFICACY AND MECHANISM EVALUATION 2018 VOL. 5 NO. 3
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Pomeroy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
23
TABLE 12 Change from baseline to follow-up for ARAT score, paretic upper limb for participants with data at both
time points
Comparison
Treatment
group
Number of
participantsa
Mean (SD) Mean (95% CI)
Baseline Follow-up Change Least squares
Least squares
difference and
p-value of change
between group
Change at
follow-up
FST + CPT 104 25.80
(18.21)
36.80
(19.14)
11.10
(14.68)
10.90
(8.31 to 13.49)
0.55
(–2.77 to 3.88);
p= 0.743
MPT+ CPT 100 27.10
(17.49)
37.40
(17.50)
10.3
(10.74)
10.35
(7.66 to 13.03)
a Number of participants with data at both baseline and follow-up.
TABLE 13 Change from baseline to outcome for grip force (kg), paretic upper limb for participants with data at
both time points
Comparison
Treatment
group
Number of
participantsa
Mean (SD) Mean (95% CI)
Baseline Outcome Change Least squares
Least squares
difference and
p-value of change
between group
Change at
outcome
FST + CPT 122 7.60 (8.72) 10.7 (9.99) 3.1 (7.11) 3.98
(2.74 to 5.21)
0.47
(–1.16 to 2.09);
p= 0.571
MPT+ CPT 115 7.20 (8.19) 9.90 (9.35) 2.70 (6.25) 3.51
(2.24 to 4.78)
a Number of participants with data at both baseline and outcome.
TABLE 14 Change from baseline to follow-up for grip force (kg), paretic upper limb for participants with data at
both time points
Comparison
Treatment
group
Number of
participantsa
Mean (SD) Mean (95% CI)
Baseline Follow-up Change Least squares
Least squares
difference and
p-value of change
between group
Change at
follow-up
FST + CPT 101 7.40 (8.50) 11.80
(10.20)
4.4 (7.02) 5.33
(3.70 to 6.95)
–0.29
(–2.37 to 1.79);
p= 0.785
MPT+ CPT 97 7.20 (8.35) 12.00
(10.10)
4.70 (8.71) 5.62
(3.95 to 7.28)
a Number of participants with data at both baseline and follow-up.
TABLE 15 Change from baseline to outcome for pinch force (kg), paretic upper limb for participants with data at
both time points
Comparison
Treatment
group
Number of
participantsa
Mean (SD) Mean (95% CI)
Baseline Outcome Change Least squares
Least squares
difference and
p-value of change
between group
Change at
outcome
FST + CPT 115 2.20 (2.20) 3.00 (2.93) 0.90 (2.13) 0.91
(0.48 to 1.33)
0.02
(–0.54 to 0.59);
p= 0.934
MPT+ CPT 109 2.00 (2.30) 2.90 (2.88) 0.90 (2.16) 0.89
(0.45 to 1.32)
a Number of participants with data at both baseline and outcome.
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TABLE 16 Change from baseline to follow-up for pinch force (kg), paretic upper limb for participants with data at
both time points
Comparison
Treatment
group
Number of
participantsa
Mean (SD) Mean (95% CI)
Baseline Follow-up Change Least squares
Least squares
difference and
p-value of change
between group
Change at
follow-up
FST + CPT 94 2.30 (2.22) 3.30 (2.45) 1.00 (2.19) 1.16
(0.62 to 1.71)
–0.30
(–0.98 to 0.39);
p= 0.395
MPT + CPT 95 2.10 (2.24) 3.50 (3.09) 1.40 (2.76) 1.46
(0.92 to 2.01)
a Number of participants with data at both baseline and follow-up.
TABLE 17 Change from baseline to outcome for WMFT performance for participants with data at both time points
Comparison
Treatment
group
Number of
participantsa
Mean (SD) Mean (95% CI)
Baseline Outcome Change Least squares
Least squares
difference and
p-value of change
between group
Change at
outcome
FST + CPT 117 36.60
(19.97)
47.80
(19.70)
11.20
(10.62)
11.31
(0.35 to 13.27)
0.65
(–1.91 to 3.21);
p= 0.616
MPT + CPT 109 39.00
(16.84)
49.00
(18.52)
10.00
(9.61)
10.65
(8.62 to 12.69)
a Number of participants with data at both baseline and outcome.
TABLE 18 Change from baseline to follow-up for WMFT performance for participants with data at both
time points
Comparison
Treatment
group
Number of
participantsa
Mean (SD) Mean (95% CI)
Baseline Follow-up Change Least squares
Least squares
difference and
p-value of change
between group
Change at
follow-up
FST + CPT 98 38.30
(19.42)
51.80
(19.83)
13.50
(14.28)
14.21
(11.53 to 16.88)
0.01
(–3.46 to 3.47);
p= 0.997
MPT + CPT 93 39.30
(16.96)
52.60
(18.41)
13.30
(11.55)
14.20
(11.40 to 17.00)
a Number of participants with data at both baseline and follow-up.
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Chapter 4 Results: neural correlates of clinical
improvement
Objective addressed
To identify the similarities and differences in the neural correlates of clinical improvement in upper limb
motor function in response to (1) FST + CPT and (2) MPT + CPT. To reiterate, baseline measures were
made immediately before randomisation and outcome measures made at the end of the 6-week
intervention phase (see Chapter 2, Design).
Flow of participants through the correlates analysis
Magnetic resonance imaging
Structural MR scans were undertaken for those participants who had no contraindications, had provided
separate informed consent for this part of the assessment and who could travel to the neuroimaging
facility. MR scans were undertaken for 94 (32.6%) participants at baseline and 62 (25.3%) participants at
outcome. Reasons for non-completion of MRI are shown in Table 19.
Transcranial magnetic stimulation
Transcranial magnetic stimulation was undertaken by those participants who had no contraindications.
The TMS measures were made with 111 (38.5%) participants at baseline and 83 (33.9%) at outcome.
Reasons for no TMS are shown in Table 20.
Neural variables at baseline and outcome
The numbers of participants for whom neuroimaging variables were available at outcome and follow-up
are shown in Tables 21–23. The number of participants varies from 45 for corticocortical and corticospinal
anatomical connectivity at outcome (see Table 21) to 84 for volume of the stroke lesion at baseline (see
Table 23).
TABLE 19 The MRI (neuroimaging) data acquisition at baseline and outcome
Data
Time point, n (%)
Baseline (N= 288)a Outcome (N= 245)a,b
MRI data acquired
Attended for neuroimaging 94 (32.6) 62 (25.3)
Reason for lack of data
Unable to attend 31 (10.8) 39 (15.9)
Did not consent 44 (15.3) 62 (25.3)
Other 119 (41.3) 106 (43.3)
a Data obtained from clinical trial unit locked (raw) database.
b Clinical trial unit data account for 269 participants in terms of attendance and non-attendance for MRI scanning.
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TABLE 20 TMS data acquisition at baseline and outcome
Data
Time point, n (%)
Baseline (N= 288)a Outcome (N= 245)a,b
TMS data acquired
Attended for TMS 111 (38.5) 83 (33.9)
Reason for lack of data
Did not consent for TMS 30 (10.4) 39 (15.9)
Unable to attend 21 (7.3) 39 (15.9)
Other 126 (43.8) 114 (46.5)
a Data obtained from clinical trial unit locked (raw) database.
b Clinical trial unit data account for 275 participants in terms of attendance and non-attendance for TMS.
TABLE 21 Corticocortical anatomical connectivity (FA MNI corpus callosum midline, range 0–1) at baseline
and outcome
Statistic
Time point
Baseline Outcome
FST+ CPT MPT+ CPT All FST+ CPT MPT+ CPT All
Number of participants 42 38 80 25 20 45
Mean 0.4 0.4 0.4 0.4 0.4 0.4
SD 0.09 0.08 0.08 0.09 0.08 0.08
Median 0.4 0.4 0.4 0.4 0.5 0.4
Minimum–maximum 0.21–0.54 0.29–0.55 0.21–0.55 0.22–0.54 0.31–0.57 0.22–0.57
IQR 0.342–0.47 0.34–0.49 0.34–0.47 0.35–0.46 0.35–0.49 0.35–0.47
IQR, interquartile range.
Final report from clinical trial unit reported to only one decimal place; however, any differences between groups would be
expected to be < 0.1 so it would be better to report two decimal places.
TABLE 22 Corticospinal anatomical connectivity (asymmetry FA CST, range –1 to 1) at baseline and outcome
Statistic
Time point
Baseline Outcome
FST+ CPT MPT+ CPT All FST+ CPT MPT+ CPT All
Number of participants 42 38 80 25 20 45
Mean 0.0 0.0 0.0 0.0 0.0 0.0
SD 0.04 0.05 0.05 0.05 0.05 0.05
Median 0.0 0.0 0.0 0.0 0.0 0.0
Minimum–maximum –0.06 to
0.14
–0.07 to
0.15
–0.07 to
0.15
–0.02 to
0.18
–0.04 to
0.18
–0.04 to
0.18
IQR 0.01 to
0.06
–0.02 to
0.06
0.001 to
0.06
0.00 to
0.07
–0.01 to
0.06
–0.01 to
0.07
IQR, interquartile range.
Final report from clinical trial unit reported to only one decimal place; however, any differences between groups would be
expected to be < 0.1 so it would be better to report two decimal places.
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TABLE 23 Volume of the stroke lesion (mm3) at baseline and outcome
Statistic
Time point
Baseline Outcome
FST+ CPT MPT+ CPT All FST+ CPT MPT+ CPT All
Number of participants 44 40 84 29 23 52
Mean 23,847.89 25,476.38 24,623.36 28,129.97 32,398.22 30,017.85
SD 47,664.63 59,957.23 53,542.90 60,884.91 57,371.06 58,818.52
Median 6537.50 2486.00 4293.00 1753.00 2139.00 1946.00
Minimum–maximum 91.00–218,162.00 56.00–324,152.00 56.00–324,152.00 99.00–252,757.00 54.00–221,613.00 54.00–252,757.00
IQR 1067.50–19,551.50 474.00–14,046.50 845.50–17,160.50 919.00–13,945.00 788.00–45,496.00 822.00–28,184.50
IQR, interquartile range.
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Change in neural variables derived from neuroimaging between baseline and outcome for those
participants with data at both visits and ARAT score data at both visits is shown in Table 24. There were
no statistically significant differences between the two groups for change in any of these variables.
The number of participants for whom neural variables derived from TMS were available at outcome and
follow-up together are shown in Tables 25 and 26. The number of participants ranges between 72 for
RMT for paretic extensor carpi radialis (pECR) at outcome (see Table 26) and 110 for presence of a MEP of
pBB and pECR at baseline (see Table 25).
Change between baseline and outcome for RMT for pBB and pECR muscles for those participants with
data at both visits and ARAT score data at both visits is shown in Table 27. There are no statistically
significant differences between the two groups for change in either of these variables.
TABLE 24 Change (outcome – baseline) in MRI variables for participants with data at both visits
Variable Group n
Mean (SD) Mean (95% CI)
Baseline Outcome Change Least squares
Least squares
difference;
p-value
Lesion volume
(mm3)
FST + CPT 24 8.20 (2.13) 8.10 (2.17) –0.10 (0.45) –0.11
(–0.31 to 0.09)
–0.12
(–0.36 to 0.13);
p= 0.349
MPT+ CPT 20 8.20 (2.49) 8.10 (2.40) –0.00 (0.32) 0.01
(–0.21 to 0.22)
Corticocortical
connectivitya
FST + CPT 20 0.38 (0.09) 0.38 (0.09) –0.00 (0.02) –0.01
(–0.02 to 0.01)
0.01
(–0.01 to 0.03);
p= 0.386
MPT+ CPT 18 0.45 (0.07) 0.43 (0.08) –0.01 (0.03) –0.02
(–0.03 to 0.00)
Corticospinal
connectivityb
FST + CPT 20 0.03 (0.05) 0.03 (0.04) 0.00 (0.01) 0.00
(–0.01 to 0.02)
–0.01
(–0.02 to 0.01);
p= 0.524
MPT+ CPT 18 0.01 (0.05) 0.031 (0.05) 0.02 (0.04) 0.01
(–0.01 to 0.03)
a FA MNI corpus callosum.
b Asymmetry ipsilesional : contralesional MNI CSTS.
TABLE 25 Presence of a MEP for pBB and pECR at baseline and outcome
MEP
Time point
Baseline Outcome
FST+ CPT MPT+ CPT All FST+ CPT MPT+ CPT All
pBB
Number 53 57 110 43 39 82
Yes, n (%) 37 (69.81) 43 (75.44) 80 (72.73) 39 (90.70) 34 (87.18) 73 (89.02)
No, n (%) 16 (30.19) 14 (24.56) 30 (27.27) 4 (9.30) 5 (12.82) 9 (10.98)
pECR
Number 53 57 110 42 39 81
Yes, n (%) 39 (73.58) 45 (78.95) 84 (76.36) 37 (88.10) 35 (89.74) 72 (88.89)
No, n (%) 14 (26.42) 12 (21.05) 26 (23.64) 5 (11.90) 4 (10.26) 9 (11.11)
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The correlations between change, from baseline to outcome, between neural variables and ARAT score
ranged from r = –0.147 (p = 0.385) for all participants’ corticospinal connectivity to r = 0.199 (p = 0.320)
for the MPT + CPT group for RMT pBB (Table 28). Consequently, the neural correlates of improvement in
ARAT score were similar for the two groups.
TABLE 26 Resting motor threshold (% of stimulator output) when MEP present in pBB (RMT pBB) and pECR
(RMT pECR) at baseline and outcome
MEP
Time point
Baseline Outcome
FST+ CPT MPT+ CPT All FST+ CPT MPT+ CPT All
pBB
Number 37 43 80 39 34 73
Mean 61.1 63.0 62.1 65.9 69.9 67.8
SD 11.49 14.39 13.08 18.12 16.59 17.42
Median 60.0 66.0 60.0 63.0 71.5 65.0
Minimum–maximum 38–98 27–85 27–98 34–96 39–98 34–98
IQR 54–66 53–74 54–70 51–76 55–85 55–85
pECR
Number 39 44 83 37 35 72
Mean 52.4 54.5 53.5 57.4 57.9 57.6
SD 12.30 15.27 13.91 18.58 16.40 17.43
Median 50.0 52.5 51.0 55.0 53.0 54.0
Minimum–maximum 24–90 27–94 24–94 27–95 33–95 27–95
IQR 46–58 44–61 45–60 47–63 44–70 44–68
IQR, interquartile range.
TABLE 27 Change (outcome – baseline) in RMT for pBB and pECR for participants with data at both visits
Variable Group n
Mean (SD) Mean (95% CI)
Baseline Outcome Change Least squares
Least squares
difference;
p-value
pBB FST + CPT 28 61.6 (12.07) 60.6 (13.61) –1.0 (14.27) –0.82
(–6.32 to 4.68)
–2.87
(–8.91 to 3.16);
p = 0.343
MPT+ CPT 27 62.5 (13.83) 65.0 (14.90) 2.5 (10.06) 2.06
(–3.86 to 7.97)
pECR FST + CPT 28 53.1 (13.15) 52.0 (11.62) –1.1 (11.46) –3.29
(–7.68 to 1.09)
0.98
(–4.31 to 6.28);
p = 0.710
MPT+ CPT 27 57.4 (17.16) 53.2 (12.93) –4.2 (12.98) –4.28
(–9.19 to 0.63)
DOI: 10.3310/eme05030 EFFICACY AND MECHANISM EVALUATION 2018 VOL. 5 NO. 3
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Pomeroy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
31
TABLE 28 Correlations between change (from baseline to outcome) in neural correlates and paretic ARAT total
score (primary outcome measure)
Neural variable
Treatment group
AllFST+ CPT MPT+ CPT
Number of
participants r-value p-value
Number of
participants r-value p-value
Number of
participants r-value p-value
Volume of the
stroke lesion
24 –0.021 0.921 19 –0.043 0.863 43 –0.042 0.787
Corticocortical
anatomical
connectivity
20 0.092 0.699 17 –0.029 0.913 37 0.069 0.684
Corticospinal
anatomical
connectivity
20 –0.031 0.897 17 –0.306 0.232 37 –0.147 0.385
RMT – pBB 28 0.095 0.631 27 0.199 0.320 55 0.093 0.501
RMT – pECR 28 –0.080 0.635 27 0.043 0.831 55 –0.001 0.996
RESULTS: NEURAL CORRELATES OF CLINICAL IMPROVEMENT
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Chapter 5 Results: predictive markers of clinical
improvement
Objective addressed
To determine if any pretreatment parameters or any combination of pretreatment parameters
[(a) anatomical location of infarction, (b) volume of the stroke lesion, (c) residual structural corticocortical
connectivity, (d) residual corticospinal connectivity and (e) brain–muscle functional connectivity (derived
from TMS)] are sufficiently predictive of upper limb recovery after stroke to enable physical therapy to be
targeted at those people most likely to respond.
Participants with neural variables data at baseline
Data on the number of participants at baseline and the values of the neural variables are presented in
Tables 21–28.
Change at outcome from baseline for Action Research Arm Test score
For those people with both ARAT score and neural variable data at baseline and outcome there were no
statistically significant interaction effects (Table 29). The data for change in ARAT score underlying these
interaction effects are provided in Tables 30–34. There are no statistically significant differences between
the subgroups for any of the baseline characteristics.
TABLE 29 Subgroup analysis of interaction effect between baseline neural variables and change in paretic ARAT
total score from baseline to outcome
Baseline characteristic Interaction p-value
Anatomical location of stroke lesion: MNI CST affected 0.384
Volume of the stroke lesion (logged) 0.762
Corticocortical anatomical connectivity (FA MNI corpus callosum midline) 0.723
Corticocortical anatomical connectivity (asymmetry ipsilesional : contralesional MNI CSTS) 0.553
Presence of MEP pBB 0.237
pBB RMT 0.697
Presence of MEP pECR 0.193
pECR RMT 0.503
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TABLE 30 Change (outcome – baseline) in paretic ARAT total score for participants with data at both visits and
measure of corticocortico anatomical connectivity
Variable Group
Number of
participants
Mean (SD) Mean (95% CI)
Baseline Outcome Change Least squares
Least squares
difference;
p-value
Corticocortical
connectivity
value below
median
FST + CPT 18 27.4 (20.29) 35.6 (17.54) 8.2 (9.47) 11.92
(6.74 to 17.10)
3.83
(–2.41 to 10.07);
p= 0.218
MPT+ CPT 14 27.4 (17.53) 34.0 (20.04) 6.6 (6.87) 8.09
(3.12 to 13.06)
Corticocortical
connectivity
value equal
to or above
median
FST + CPT 18 22.3 (18.22) 39.3 (14.58) 17.1 (13.45) 16.95
(11.22 to 22.68)
4.29
(–2.99 to 11.58);
p= 0.238
MPT+ CPT 18 24.6 (17.74) 33.8 (19.65) 9.2 (6.78) 12.66
(5.40 to 19.92)
TABLE 31 Change (outcome – baseline) in paretic ARAT total score for participants with data at both visits and
measure of stroke lesion volume
Variable Group
Number of
participants
Mean (SD) Mean (95% CI)
Baseline Outcome Change Least squares
Least squares
difference;
p-value
Lesion volume
value below
median
FST + CPT 17 25.1 (18.64) 41.2 (14.91) 16.1 (11.99) 16.05
(10.71 to 21.38)
5.3
(–1.09 to 11.70)
p= 0.101
MPT+ CPT 20 28.7 (18.96) 38.3 (18.26) 9.7 (8.03) 10.74
(5.62 to 15.87)
Lesion volume
value equal
to or above
median
FST + CPT 21 22.8 (19.99) 32.5 (17.44) 9.8 (12.36) 12.59
(6.22 to 18.96)
4.44
(–2.89 to 11.76)
p= 0.225
MPT+ CPT 14 22.4 (16.98) 27.7 (19.57) 5.4 (5.39) 8.15
(0.02 to 16.29)
TABLE 32 Change (outcome – baseline) in paretic ARAT total score for participants with data at both visits and
measure of anatomical overlap of the stroke lesion with the CST
Variable Group
Number of
participants
Mean (SD) Mean (95% CI)
Baseline Outcome Change Least squares
Least squares
difference;
p-value
CST
lesioned = yes
FST + CPT 33 23.3 (19.67) 35.2 (17.35) 11.9 (12.32) 13.9
(9.55 to 18.29)
2.88
(–2.29 to 8.04);
p= 0.269
MPT+ CPT 27 25.7 (17.04) 34.0 (18.77) 8.30 (7.40) 11.0
(6.48 to 15.60)
CST
lesioned = no
FST + CPT 5 27.0 (17.07) 44.2 (9.42) 17.2 (13.65) 26.1
(–9.59 to 61.82)
20.64
(–14.07 to 55.36);
p= 0.187
MPT+ CPT 7 27.6 (23.59) 33.7 (22.63) 6.1 (7.13) 5.5
(–12.28 to 23.22)
RESULTS: PREDICTIVE MARKERS OF CLINICAL IMPROVEMENT
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TABLE 33 Change (outcome – baseline) in paretic ARAT total score for participants with data at both visits and
measure of asymmetry of the ipsilesional and contralesional CST connectivity
Variable Group
Number of
participants
Mean (SD) Mean (95% CI)
Baseline Outcome Change Least squares
Least squares
difference;
p-value
Ratio value
below median
FST + CPT 19 28.6 (16.69) 43.2 (11.54) 14.6 (11.90) 14.90
(8.84 to 20.96)
2.42
(–3.95 to 8.79)
p= 0.443
MPT+ CPT 16 31.9 (15.80) 42.4 (16.15) 10.4 (6.65) 12.48
(6.55 to 18.42)
Ratio value
equal to or
above median
FST + CPT 17 20.6 (21.36) 31.1 (18.11) 10.4 (12.73) 15.38
(7.81 to 22.95)
6.62
(–0.33 to 13.56)
p= 0.061
MPT+ CPT 16 19.7 (17.26) 25.4 (19.26) 5.7 (6.35) 8.76
(1.51 to 16.02)
TABLE 34 Change (outcome – baseline) in paretic ARAT total score for participants with data at both visits and
measure of MEP in pBB and pECR
Variable Group
Number of
participants
Mean (SD) Mean (95% CI)
Baseline Outcome Change Least squares
Least squares
difference;
p-value
MEP pBB = yes FST + CPT 34 32.2 (16.69) 43.0 (12.76) 10.9 (11.85) 11.68
(8.24 to 15.12)
3.19
(–0.71 to 7.09);
p = 0.107
MPT+ CPT 36 34.0 (15.05) 40.3 (14.34) 6.2 (7.95) 8.49
(5.04 to 11.93)
MEP pBB = no FST + CPT 16 12.6 (15.34) 22.1 (21.30) 9.4 (11.43) 11.62
(3.68 to 19.56)
–0.60
(–7.38 to 6.18);
p = 0.856
MPT+ CPT 13 12.7 (13.31) 22.2 (16.60) 9.5 (7.41) 12.22
(3.07 to 21.37)
MEP pECR = yes FST + CPT 36 31.9 (16.87) 43.6 (12.87) 11.7 (12.37) 12.67
(9.31 to 16.03)
3.41
(–0.53 to 7.34);
p = 0.089
MPT+ CPT 38 33.8 (14.60) 40.6 (13.43) 6.8 (7.52) 9.26
(5.89 to 12.64)
MEP pECR = no FST + CPT 14 10.4 (13.15) 17.5 (18.15) 7.1 (8.98) 14.97
(–2.04 to 31.98)
–1.74
(–9.54 to 6.07);
p = 0.646
MPT+ CPT 11 9.7 (12.62) 17.8 (15.87) 8.1 (9.31) 16.71
(–1.18 to 34.60)
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Chapter 6 Discussion
The present trial combined investigation of the clinical efficacy of MPT and FST together with(1) identification of the neural correlates of response to therapy as a basis for identifying precise therapy
target(s) and (2) understanding whether or not neural characteristics at baseline could indicate response
to MPT and FST and thereby identify which stroke survivors should receive which of these therapies.
Hence, investigating efficacy and mechanisms together in the present trial provides robust information
for subsequent definitive trials to investigate the effectiveness of MPT and FST targeted at the underlying
central nervous system mechanisms of their means of action in those people most likely to respond. The
need for such research has been highlighted by the UK Academy of Medical Sciences,55 the US National
Institutes of Health16 and an international consensus group.15
Summary of main results
Clinical efficacy: summary of main results
This study found little difference between the groups in upper limb recovery in response to the two forms
of physical therapy. Differences did not reach statistical significance. Importantly, the variability in response
within groups was considerable, especially for (hand) grip force and (finger) pinch force.
Neural correlates of clinical improvement: summary of main results
This study found no clinically important association between clinical improvement and change in the neural
measures in response to either trial intervention. However, the sample sizes available for analysis of neural
therapy interactions were small. Therefore, there was little chance of detecting any significant probability.
Predictive markers of clinical improvement: summary of main results
This study found no interaction effects between baseline neural variables and change in ARAT total score
(primary outcome measure) for the paretic upper limb between baseline and outcome (primary time point).
As for the neural correlates of clinical improvement analysis, the sample sizes available for analysis of
neural therapy interactions were small, which gave little chance of detecting significant probability.
Strengths and limitations
Bias protection for this trial was provided by the blinding of assessors to group allocation, concealment
of randomisation order, group allocation via independent telephone randomisation service, adhering to
the intention-to-treat principle and reporting all planned outcomes. This trial evaluated a behavioural
intervention and, therefore, it was not possible to blind research therapists, participants or clinical staff to
the allocated intervention. Although this is perceived as a distinct limitation in drug trials, it is recognised
that double blinding is not possible in trials of many stroke rehabilitation interventions. Because of staffing
challenges in centres at some points in the trial, it was not always possible to have blinded assessment of the
behavioural outcomes.
The sample size for this trial was estimated by a power calculation informed by data from our early-phase
trial.28 The estimated sample size allowed for an attrition rate of 10% at the primary end point of outcome.
In the event our attrition rate at outcome was 12.5%, which is substantially lower than the 25% reported
by the well-regarded EXCITE (Extremity Constraint-Induced Therapy Evaluation) trial of CIMT.56
This trial was congruent with the requirements for stroke rehabilitation trials.40 A strength for all aspects of
this trial is that the interventions, both MPT and FST, were described in sufficient detail to enable both
research replication of the trial and transferability of results to clinical practice.48,57,58 Thus, this trial has
followed the recommendations for improving rehabilitation research.57,59
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The experimental FST + CPT in this trial was consistent with key principles of neural plasticity9,60 and was
therefore well placed to (1) exhibit clinical efficacy and (2) form a useful probe of correlates of, and
indicators for, upper limb recovery.
Clinical efficacy: strengths and limitations
An important strength of the trial reported here is that 59% of participants were recruited within 30 days
of stroke. Early rehabilitation is recommended because the brain has most potential for reorganisation
particularly in the first month after stroke but also in the following 2 months.9 In clinical practice, most
rehabilitation is provided in this early period and yet most rehabilitation trials are conducted later in
recovery. A recent systematic review found that only 5.6% of identified RCTs met a required quality
threshold and were conducted within the first month after stroke.61 Therefore, the present trial is likely to
be important for stroke rehabilitation research and practice.
Another strength of the trial is that the sample did not just include stroke survivors with mild paresis after
stroke who were therefore expected to make a good recovery. The participants in this trial are representative
of those who receive upper limb rehabilitation in clinical stroke services. The results are therefore directly
relevant to clinical practice.
The power calculation that informed the sample size for this trial accounted for the clustering of
participants within therapists. In the event, staff turnover and securing of additional resource in the form
of additional therapists meant that many more therapists than anticipated initially provided either MPT or FST
to participants in this trial. Although this is a limitation in terms of not allowing for the clustering analysis, it is
also a strength as a greater number of therapists indicates higher generalisability to the clinical environment.
Neural correlates of clinical improvement: strengths and limitations
A key strength of this mechanistic study is that it was embedded within a robust clinical trial. Thus, unlike
many mechanistic studies, the one reported here guarded against potential risk of bias and allowed for
sufficient description of the interventions provided. Although the number of participants in this mechanistic
study was lower than anticipated, it still recruited many more participants than many such studies.
This analysis was restricted by the low proportion of participants who had both (1) full sets of clinical data
and (2) neural measures at the key time points of baseline and outcome. This ranged from 37 participants
for corticocortical anatomical connectivity to 55 participants for RMT in pBB and pECR muscles.
Predictive markers of clinical improvement: strengths and limitations
Again, as for the neural correlates study, being embedded in a RCT provides strength to this mechanistic
study. However, it was disappointing that a greater number of participants were unable to be included in
the analysis. On the other hand, we have shown that it is possible to conduct mechanistic neural studies in
pragmatic clinical trials. Furthermore, we have shown that these highly specialised neural measures can be
made in clinical settings that are not associated with specialist neurological centres and have not previously
conducted these mechanistic investigations. However, the challenges to this approach are evident in the
number of measures not undertaken for ‘other’ reasons (see Tables 19 and 20).
Relationship to previous studies
Progress in stroke rehabilitation has been hampered by a paucity of large-scale projects in which
neuroscientists and clinicians have been able to work together and so inform each other’s approach to
a single clinical problem, such as the treatment of upper limb weakness.55 For this trial, we combined
neuroscience and clinical science expertise in the largest study of its kind to investigate underlying
mechanisms of motor recovery in a representative sample of patients early after stroke with substantial to
moderate upper limb motor impairment using well-characterised physical therapies.
DISCUSSION
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Clinical efficacy: relationship to previous studies
The results of the trial reported here build on early-phase findings that suggest a trend towards better
upper limb recovery, as assessed by ARAT score, in response to FST + CPT compared with MPT + CPT
early after stroke.28 However, the findings of the present trial, with a larger sample size, showed no
difference between FST + CPT and MPT + CPT in respect of improvement of ARAT score over the 6-week
intervention phase.
That MPT + CPT was found to produce equivalent benefit to FST + CPT is interesting, as FST is based on
the findings that task-specific training drives recovery after stroke7 and that the largest impact on upper
limb improvement is loss of muscle strength.18,19 In contrast, MPT concentrates on enhancing the quality
of movement during whole or part functional tasks and not on repetitive progressive training of those
everyday tasks. Although there is some evidence of effect of such impairment-based therapy,38 a
meta-analysis found that conceptually different physical therapies have equal efficacy.39
Noticeable from these results is that there is substantial variation around the mean change from baseline
for both FST + CPT and MPT + CPT (see Tables 11–18). Therefore, the present findings support the concept
underlying the scientific driver for this trial, namely that stroke survivors respond differently to different
physical therapies.19
Neural correlates of clinical improvement: relationship to previous studies
Published studies report that there are different neural changes for physical therapies found to have
more benefit than the comparator intervention.60,62–64 However, the trial reported here found that the
mean changes of ARAT score (primary outcome) in response to both interventions were above the clinical
important difference of six points (see Table 11), although there was not a statistically significant difference
between the groups, and there were no differences between the groups for the potential mechanisms
of recovery of corticocortical connectivity, corticospinal connectivity or RMT of corticospinal functional
connectivity for both muscles of interest (see Tables 24 and 27). Earlier studies have been smaller in scale
(e.g. n = 13,62 n = 12,60 n = 1463 and n = 2364) than the present trial, but the trial reported here had larger
sample sizes for the MRI variable (n = 38) and the TMS variables (n = 55). Another important difference to
the present trial is that earlier studies show a potential risk of bias in the method of randomisation60,62,63
and the use of blinded assessors60,62 and selective recruitment,60,63 and one study was a post hoc analysis
of a single-centre RCT.64
Predictive markers of clinical improvement: relationship to previous studies
Although identification of clinical prediction rules for physical therapy interventions is a research priority in
physical rehabilitation, a systematic review identified only six RCTs.65 None of the identified publications
was concerned with stroke rehabilitation.65 It follows that the trial reported here is most likely one of the
first trials designed to identify predictive markers of response to specific physical therapies early after
stroke. Other investigations have been reported but are limited for use with people early after stroke
because of lack of a comparator group, lack of specification of the therapy and/or lack of participants in
the chronic phase after stroke.24,66,67
Generalisability
The generalisability of this trial is considered in the wide inclusion criteria with direct relevance to clinical
practice and the conduct of the trial in three different clinical centres.
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Chapter 7 Conclusions
Objective 1
The trial reported here found small differences in the clinical efficacy of upper limb recovery between
FST + CPT and MPT + CPT, but these did not reach statistical significance. Both groups showed increases in
ARAT score (primary outcome measure) above the clinically important change. However, variation around
the mean change from baseline scores was substantial in both groups.
Objective 2
The neural correlates of change were similar for the two forms of physical therapy. There were no
statistically significant correlations between change in the neural correlates and change in clinical
efficacy measures.
Objective 3
The trial reported here found that none of the pretreatment neural characteristics of interest predicted
response to either FST + CPT or MPT + CPT.
Implications for health care
The findings of the trial reported here confirm clinical impressions and emerging research evidence of
variation in response to specific therapies among people early after stroke.
Research recommendations
There is still an urgent need for evidence to guide decisions about (1) appropriate prescription of physical
therapy for individuals and (2) the recovery mechanisms at which physical therapy should be targeted.
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Appendix 1 The conventional physical therapy,
therapy as usual, intervention
Aims 
1.  To reduce pain  3.  To improve muscle activity/function  5.  To improve gross mobility  
2.  To improve sensory awareness  4.  To improve postural control  6.  To improve endurance  
Gross position of patient during activities used 
1.  Supine lying  4. non-paretic side lying  7.  4 pt kneeling  10.   Standing   
2.  Crook lying  5.  Sitting - 900  8.  2 pt kneeling  11.   Walking  
3.  Paretic side lying  6.  Sitting – perch  9.  ½ kneeling  12.  Other  
Equipment used  
1.  High hold/surface  4.  Perching stool  7.   Walking aid  10.  Other  
2.  Low hold/surface  5.  Rolled up towel  8.  Tilt table    
3. Hip high hold/surface  6.  Gym ball  9.   Standing frame    
Specific Physical Therapy interventions 
1.   Soft tissue mobilisation 
1.1   Specific soft tissue mobilisation  
1.2   Passive movement  
1.3   Muscle stretching  
2.   Facilitation of activity in specific muscles 
2.1   Imagery of specific muscle activity  
2.2   Specific muscle activation  
2.3   Activation of muscle activity during function  
3.   Facilitation of isolated (selective) joint movement    
3.1   Imagery specific joint movement  
3.2   Active assisted isolated joint movement  
3.3   Facilitate specific joint movement during function   
4. Facilitation of co-ordinated (combined) movement  
4.1.   Imagery of co-ordinated patterns of movement  
4.2   Active assisted co-ordinated patterns of movement  
4.3   Facilitate co-ordinated movement during function  
4.4   Facilitate leg/foot activity from another body part  
5. Resistive exercise  
5.1   Resistance from therapist  
5.2   Resistance from patient’s bodyweight  
5.3   Resistance from equipment  
6. Specific sensory (tactile & proprioceptive) input  
6.1   “Hands-on” techniques  
6.2   Provision of environmental surface  
7. Splinting techniques  
7.1   Strapping  
7.2   Splinting  
 
8. Function – in lying towards sitting 
8.1   PT “hands-on” techniques to re-ed posture  
8.2   Re-ed of funct act through specific mvmnt patterns  
8.3   Rolling – functional activity training  
8.4.  Bridging - functional activity training  
8.5   Lying to sitting – functional activity training  
8.6   Sitting to lying  - functional activity training  
8.7   Static sitting balance training  
9.Function – In sitting towards standing  
9.1   PT “hands-on” techniques to re-ed posture  
9.2   Re-ed of funct act through specific mvmnt patterns  
9.3   Dynamic sitting balance training  
9.4   Transfers training  
9.5   Sit to standing – functional activity training  
9.6   Stand to sit – functional activity training  
10. Function – In standing towards walking  
10.1  PT “hands-on” techniques to re-ed posture  
10.2  Re-ed of funct act through specific mvmnt patterns  
10.3  Static standing balance training  
10.4  Dynamic standing balance training  
10.5 One leg stand activities – functional training  
11. Function – Walking and onwards 
11.1  PT “hands-on” techniques to re-ed posture  
11.2  Re-ed of funct act through specific mvmnt patterns  
11.3  Overground indoor walking training  
11.4  Overground outdoor walking training  
11.5  Treadmill walking/bicycle training  
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Instructions for completion of recording form 
1. ONE FORM FOR EACH TREATMENT SESSION 
Please complete one form for each treatment session given to patients included as subjects in the 
Functional Strength Training lower limb clinical trial 
2. TO COMPLETE THE AIMS SECTION  
Please place a tick in the box which best describes the aims relevant to the particular treatment 
session being recorded 
3. TO COMPLETE THE GROSS POSITION SECTION 
Please place a tick in the box for every gross position used to deliver physiotherapy treatment 
during the treatment session being recorded 
4. TO COMPLETE THE EQUIPMENT SECTION 
Please place a tick in the boxes which best describes the equipment used during the particular 
treatment session being recorded 
5. TO COMPLETE THE SECTION “SPECIFIC PHYSICAL THERAPY INTERVENTIONS” 
Please place a tick in the boxes which best describe the treatment that was given to the patient 
during the particular treatment session being recorded. 
6. FOR FURTHER DESCRIPTION OF ITEMS ON RECORDING FORM OVERLEAF 
Please refer to the accompanying document “Description of Lower Limb Treatment for Patients in 
FST Trial” 
7. COMPLETED FORMS GIVEN TO RESEARCH TEAM 
When forms are complete please pass to a member of the research team 
 
Abbreviations for and glossary of terms used in recording form  
Act Activity/activities 
Environmental surface A surface to enhance  sensory input during functional activity e.g. sitting 
on a block of foam, walking on an exercise mat, walking on uneven 
ground 
Facilitation The application of an appropriate mode and dose (frequency, duration and 
intensity) of sensory stimulus provided by the therapist to access a desired 
active response from the patient 
Funct Function/functional 
High hold/surface A surface level with at least the mid-thoracic point of the patient to 
provide a hold and/or security during physical therapy intervention  
Imagery Mental rehearsal of a motor act that occurs in the absence of overt motor 
output 
Low hold/surface A surface level between the hip and mid-thoracic point of the patient to 
provide a hold and/or security during  physical therapy intervention 
Mvmnt Movement 
Physiotherapist Person with professional Physiotherapy qualification 
PT Physical Therapy 
Re-ed Re-education 
Rehabilitation Assistant Person assisting the physiotherapist but who is not a qualified 
physiotherapist (e.g. student, nurse, technician, carer) 
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Appendix 2 Training update days for research
therapists
T raining in delivering each of the trial interventions, MPT and FST, was provided for all research therapistsemployed to deliver the trial intervention; this was initially completed before the first participant was
recruited at each site. Each therapist was ultimately allocated to one intervention only and undertook specific
training in the allocated intervention. However, it was important that each therapist also had an awareness
of the non-allocated intervention in order to fully understand the differences and similarities between each
intervention/approach (MPT and FST) and, therefore, the parameters of each of the trial interventions.
During the trial there was a turnover in research therapist staffing, and as each new research therapist came
into post during the trial, this initial training was also provided on an individual basis with subsequent and
ongoing peer mentorship and networking from the research therapists delivering trial intervention at the
other sites.
In addition to initial training, two training update days were held during the recruitment phase of the trial.
All research therapists employed to deliver trial intervention at that time attended these sessions. Both
training update days were held in London over a period of 2 consecutive days. Through these update days,
the within-trial research therapist networking was maintained and enhanced, enabling the research therapists
to consult regularly with their peers providing the same trial intervention, but in different centres, to talk
through understandings and practice. The trial manager and two of the other authors, Susan Hunter and
Valerie Pomeroy, were also involved in these networking conversations.
Training update dates: 7 November 2013 and 6–7 July 2015.
Venue: both training update days were held in London, one at UEA London (November 2013) and another
at the Premier Inn Hotel, London Victoria (July 2015).
Facilitators/trainers: Valerie Pomeroy and Susan Hunter.
Programme/content of the day: see programmes to follow.
Format: open structured discussion, small-group work with whole-group feedback and discussion
(see following for summary of discussion and key actions/decisions agreed by the team).
FAST-INdICATE training: delivering trial intervention – November 2013,
UEA, London
Day 1
Session 1: 11.15–13.30
1. Plan for the day.
2. Experiences of delivering therapy so far – whole-group discussion.
3. Identify specific topics for the 2 days – whole-group discussion.
4. MPT and FST groups – discussion around therapy for various patient presentations and problems:
a. low/high tone
b. shoulder subluxation/pain
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c. low/high ability
d. cognitive/perceptual problems
e. somatosensory loss.
5. Feedback from groups on therapy delivered by each team for a patient with low tone/low ability;
discussion of differences between the two approaches (e.g. hands-on/hands-off; starting position/
postural control).
Lunch 13.30–14.15
Session 2: 14.15–16.15
1. Feedback and discussion about therapy for the high-ability patient, particularly issues related to
dexterity and progression for both MPT and FST.
2. Discussion/clarification around fundamental differences between MPT and FST, and how they might
appear to be similar but remain different (e.g. progressive strengthening vs. task practice, strength vs.
endurance, feedback, facilitation vs. guidance vs. active-assisted exercise) and what is a ‘middle therapy’
(i.e. neither MPT nor FST) (e.g. immersion of limb in water bath/’hydrotherapy’/use of hydrotherapy
principles such as buoyancy/effect of temperature on tone and pain/stiffness).
Day 2
Session 3: 9.00–10.30
1. Self-directed therapy – what is involved, how is it monitored, how are instructions communicated to
participants, how is it recorded, what is appropriate content, overcoming cognitive/memory difficulties,
leaving equipment with patients and related issues of blinding, etc.
Session 4: 11.00–12.30
1. Documentation of therapy – inclusion of number of ‘reps’?
2. Adverse event reporting.
3. ‘Middle therapies’ that are neither MPT or FST, for example hydrotherapy, pulleys, FES.
4. Feedback/evaluation.
12.30 Lunch and close
Topics identified for discussion and actions agreed during the training
1. Therapist-directed and participant-administered therapy.
l Specific equipment that was required for FST would be provided by the research therapist. However,
written instructions would not be provided by the therapist, but the participant or carer could make
notes to remind them of what exercises they should do, and when/how often they should do them.
l It was noted that hand dominance and side of hemiplegia potentially impacted on the ability to
complete this participant-administered therapy.
l The presence/involvement of a carer or spouse was likely to be helpful in participants administering
their own therapy/exercises.
l Variability and non-standardisation of this directed therapy was important because of
personalised care.
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
56
2. Equipment left at participant’s house for directed therapy.
l There is a potential threat to blinding if equipment that is obviously specific to FST is left at the
participant’s home and seen by the clinical team. Its presence may confound the content of CPT,
as the clinical team might be tempted to use this equipment in their CPT programme with that
participant, thus increasing the dose of FST and changing the nature of actual CPT.
l There was a suggestion that the content of CPT should be analysed for both groups to see if it is
affected by group allocation (i.e. whether or not there is more strength training activity for the FST
group), which might be a result of the presence of strengthening equipment in the home.
3. Documenting therapy.
l It was agreed that the number of repetitions of an exercise/activity in the FST group would not
be reported.
4. Progression of dexterity activities in high-functioning participants.
l This was discussed in the context of generating ideas for progression exercises to improve dexterity
in high-functioning participants and the difficulty this presents was acknowledged.
5. Difference between strength and endurance training/activities in FST.
l Discussed and number of repetitions for strengthening to be based on six repetition maximum,
whereas number of repetitions for endurance to be based on three sets of 10–12 repetitions.
6. Use of feedback and the difference between knowledge of performance and knowledge of results.
l Knowledge of performance is characterised by a focus on movement (body part, direction/plane,
e.g. bend, straighten elbow), whereas knowledge of results is characterised by a focus on
quantitative measure of goal achievement (e.g. moving an object a set distance).
7. Use of active-assisted exercise/movement and facilitation in FST.
l Neither active-assisted nor facilitated movement is acceptable as part of FST; however, providing
support to a body part in order to minimise the effect of gravity as part of a progressive
strengthening regime is acceptable as long as the support is simply supporting the weight of the
limb and not assisting with movement.
8. Adverse event reporting.
l Pain and fatigue are to be monitored at each therapy visit to identify adverse reactions to the therapy:
¢ A change in two levels on the Motricity Index that occurs on four consecutive occasions is to be
considered an adverse reaction of fatigue (AE on the CRFs).
¢ The presence of new pain over four consecutive occasions is to be considered an adverse reaction
of pain (AE on CRFs) only if the pain cannot be explained by the clinical team as resulting from a
different cause. If a participant reports new pain, the research therapist or PI will contact the clinical
team to determine whether the new pain is likely to be cause by the trial intervention or if there is
another explanation for that pain. If that new pain is present on four consecutive visits by the research
therapist is considered to be attributable to the trial therapy, then an AE form should be completed.
If the pain is not considered to be attributable to the trial intervention, then it is not necessary to
complete an AE form but an e-mail trail of the discussion with the clinician should be kept and stored.
¢ If there is pre-existing pain at the start of the trial, this should not be recorded on the pain and
fatigue form; a record should be made of this pain only if it changes in intensity or nature.
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9. Use of ‘special’ equipment and ‘middle therapies’ that could constitute a different intervention.
l It was agreed that neither pulleys, nor FES, nor water bath/hydrotherapy should not be used for
MPT or FST exercises.
l TheraBand® (TheraBand, Akron, OH, USA) is acceptable for strength training as part of FST.
l Throwing and catching a ball is an acceptable activity for FST or MPT; however, the use of the ball
and progression of exercise would be subtly different for each intervention.
Training evaluation: research therapists, UEA, 7 November 2013
After the training had been completed in November 2013, the research therapists and trial manager were
asked to summarise what they had gained most from the training. The following were the verbal
responses received:
l Greater understanding of the trial interventions – able to now differentiate between MPT and FST.
This was reassuring and insightful.
l Astounded by the quality of the team.
l Reaffirming similarities of therapy between centres.
l Team building – knowing everyone better.
l Getting to know people; links for further discussions.
l Discussion at length to clarify treatment – clinically reason choices.
l Clarification re MPT and function and scope of what can be done.
l New ideas for new members of the team.
l Insight into MPT.
l Increased scope of what can be done in MPT and FST.
l Clarification re paperwork, especially AEs.
l Focus on feedback given to patients.
l Increased treatment options.
FAST-INdICATE training: London, 6–7 July 2015
Day 1: Monday 6 July 2015
1. Plan for the day.
2. Experiences of delivering therapy so far: good and not so good – whole-group discussion.
3. Identify specific topics for the 2 days – whole-group discussion.
4. MPT and FST groups – discussion around therapy you would deliver for:
a. Patient with low tone
b. Patient with high tone
c. Patient with shoulder subluxation/pain
d. Low-ability patient
e. High-ability patient
f. Patient with cognitive/perceptual problems
g. Patient with somatosensory loss.
5. Feedback from groups on therapy delivered by each team for patient with low tone/low ability;
discussion of differences between the two approaches (e.g. hands-on/hands-off); starting position/
postural control.
6. Feedback and discussion about therapy for the high-ability patient, particularly issues related to
dexterity and progression for both MPT and FST.
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Day 2: Tuesday 7 July 2015
1. Val Pomeroy to present an update on the mechanisms of recovery and predictors of stroke
rehabilitation response.
2. Discussion/clarification around fundamental differences between MPT and FST, and how they might
appear to be similar but remain different (e.g. progressive strengthening vs. task practice, strength vs.
endurance, feedback, facilitation vs. guidance vs. active-assisted exercise); and what is a ‘middle
therapy’ (i.e. neither MPT nor FST) (e.g. immersion of limb in water bath/’hydrotherapy’/use of
hydrotherapy principles such as buoyancy/effect of temperature on tone and pain/stiffness).
3. Self-directed therapy – what is involved, how is it monitored, how are instructions communicated to
participants, how is it recorded, appropriate content, overcoming cognitive/memory difficulties, leaving
equipment with pts and issues of blinding, etc.
4. Claire and Liz to lead a discussion on trial assessment procedures.
5. Feedback/evaluation.
Close
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Appendix 3 Description of movement
performance therapy
The trial intervention MPT was formerly referred to as the control intervention CPT in our earlier trialsand publications, and the content of MPT remains the same as for CPT described earlier in this paper.
This intervention is intended to reflect a typical UK physiotherapy treatment for stroke. MPT emphasises
therapy interventions provided by a therapist using predominantly hands-on facilitation and guiding
movement (therapist dependent) to provide somatosensory stimulation and to optimise joint and body part
alignment in preparation for voluntary movement. Some iterative practice of functional tasks is included
but without systematic progression in resistance to movement or repetition. A manual was produced to
support therapists delivering MPT, which clarifies terminology, etc. This has been appended in this section.
The TIDier checklist format has been used to summarise and describe MPT (Table 35).
TABLE 35 Summary and description of MPT
Brief name MPT
Why?
Describe any rationale, theory or
goal of the elements essential to
the intervention
MPT is a part of established CPT, which is supported by a very limited research
evidence base. MPT therapy content was first developed through literature reviews and
iteratively with senior, experienced neuro-physiotherapists, who described in detail the
therapy techniques and interventions they used in routine UK clinical practice to retrain
sensorimotor function and movement in the hemiplegic upper limb following stroke;
from this description, a schedule of treatment was developed and validated to provide
a way of recording the content and amount of MPT provided for people presenting
with upper limb motor impairment after stroke (Hunter et al., 2006;68 Donaldson
et al., 200946). MPT is focused on:
1. Improving the quality and normality of movement in terms of fluidity (smoothness),
co-ordination of upper limb segments and minimisation of effort to achieve efficient
functional movement
2. Postural control and joint and muscle alignment in preparation for voluntary
movement
3. Therapeutic handling (tactile cues through manual contact) to facilitate or inhibit
motor system activity underlying the performance of movement required for
functional tasks
The purpose of the various techniques that together make up the ‘module’ of MPT
include:
l Enhance recovery of sensory function and ability
l Enhance musculoskeletal alignment and range of motion
l Enhance the production of appropriate muscle activity in the paretic and
non-paretic upper limb
l Prevent or reduce pain and other secondary complications
l Enhance recovery of the quality and normality of voluntary movement in terms of
fluidity (smoothness), co-ordination of upper limb segments and minimisation
of effort
l Enhance recovery of postural control
l Enhance recovery of transport ability of the paretic arm
l Enhance recovery of manipulative ability of the paretic hand
continued
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TABLE 35 Summary and description of MPT (continued )
Brief name MPT
What?
Materials: describe any physical
or informational materials used
in the intervention, including
those provided to participants or
used in intervention delivery or
in training of intervention
providers. Provide information
on where the materials can be
accessed (e.g. online appendix,
URL)
Procedures: describe each
of the procedures, activities,
and/or processes used in the
intervention, including any
enabling or support
Quality of movement is emphasised during performance of a task. Participants are
encouraged to practice activities such as grasp/release, reaching to objects, pointing
in space, but not always as part of a specific functional task. During these activities,
the therapist monitors and regulates quality of postural alignment and voluntary
movement using hands-on techniques
Before any voluntary movement is attempted by the participant, the therapist uses
appropriate techniques to ensure that participants are in the optimum gross body
posture for the movement, and that the joints and segments of the upper limb are in
the correct alignment. During the voluntary production of movement, the therapist will
use ‘hands-on’ techniques to maintain the optimal posture and alignment for the
specific activity. Moreover, treatment activities are used in combination; for example, a
participant might perform voluntary reaching for a cube, and the therapist may have
provided some stroking to the skin overlying the forearm extensor muscles, and passive
movement of the elbow joint, as a precursor to the voluntary movement. This would
have been to provide sensory stimulation to the limb and increase the participant’s
awareness of/attention to the limb segments and joints that need to be controlled
during that movement. The therapist might also provide some active assistance during
the reaching movement to ensure that the movement was smooth. Thus, the
treatment activities are designed to be used in different combinations for different
individuals depending on their ability to produce high-quality voluntary movement
Treatment progression is determined by the therapist using clinical reasoning to inform
how to change within and between activities to improve the production of quality
movement. The process of clinical reasoning incorporates a range of variables including
participant motivation, cognition, mood, response to previous activity and long term
goals. Resultant clinical decisions may include changing the objects used, the spatial-
temporal framework for movement, the focus of the activity and the activities
themselves. There is no systematic progression in terms of objects, treatment activities
or number of repetitions of an activity. Indeed, the emphasis is the production of
quality movement underpinning normal performance of everyday functional tasks
which need to be performed in different environmental contexts
Motivation through goal-setting
It is essential that participants feel motivated to engage in the intervention.
Goal-setting can enhance motivation and clinical guidelines stress that it is an integral
part of stroke rehabilitation (RCP, 201669). Therefore, the therapist and participant will
discuss the activities that will be prioritised and document these on the intervention
record sheets
Engaging in therapeutic activities
The therapist assesses the participant’s ability to perform a movement, such as
reaching for a therapeutic object (ball/block/cone) and notes the movement
components that are difficulty to perform with normal quality. The therapist will also
note the blocks to quality movement. This assessment is based on expert knowledge of
normal movement sequences and postural control. Clinical reasoning is employed to
determine which components/elements are deficient for individual participants at
different times in their recovery after stroke
Practice
Assessment would start with whole practice of a functional task with a therapeutic
object to enable the therapist and participant to identify which components (if any)
can be performed normally (with quality). Whole practice is only used if the participant
is able to produce quality movement throughout. This may enhance motivation
especially if used to emphasise how much improvement has been made. However,
it will often be the case that hands-on therapy techniques are required to produce
quality movement and, in this case, activity should focus upon the components that
are problematic. When possible, the activity session should ideally finish with whole
practice to enable the participant to put the components into context, and practice the
dynamics of a task as a whole (and thus the entire motor programme)
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TABLE 35 Summary and description of MPT (continued )
Brief name MPT
Constant practice involves the repetition of identical movement; variable practice
involves practice of different variations of the same category of movement. Movement
patterns underlying everyday functional activities are inherently variable, so MPT will
encourage variable practice by, for example, using different start and end points
(e.g. reaching in different directions), movement from different postures (e.g. sitting/
standing) and using different therapeutic handling techniques
Feedback
Augmented feedback (i.e. feedback provided by the therapist) is one of the most
important influences in the process of acquiring movement skill and, therefore, its
application needs to be carefully considered (Schmidt and Lee, 1999;70 Magil, 2001;71
Wulf et al., 199372). Augmented feedback pertains either to the quality (pattern) or the
outcome of the movement:
a. Feedback about the movement pattern is known as knowledge of performance;
an example is stating to a participant that they bent sideways during reaching
b. Feedback about the movement outcome is known as knowledge of results; for
example, telling a participant how long it took them to reach for the object
MPT feedback emphasises knowledge of performance. This emphasis will encourage an
internal focus on the body parts involved in producing quality movement. The therapist
will give prominence to the provision of information for movement and feedback during
its performance through tactile input during therapeutic handling. For example, during
active-assisted movement the therapist may guide the path taken by the hand during a
reaching activity and thus provide sensory input to the participant about how the speed
and direction required for quality movement. Any verbal feedback provided will direct
the participant’s attention to the guidance from the therapist’s hands. Emphasis will
also be given to encouraging participants to focus on how the movement feels and
how individual joints/segments of the body are moving. For example, during reaching
forwards, feedback could be given on movement of the elbow rather than the success of
grasping the target (e.g. ‘next time keep you elbow closer to your body’). As the content
of feedback depends on the performance of each individual participant, no attempt is
made to standardise this. It is a strong requirement, however, that the research therapist
is an expert in therapeutic handling with extensive knowledge of, and clinical experience
in, the science of normal movement
Amount and frequency of feedback
A faded feedback schedule is recommended, whereby feedback is given frequently in the
early stage of learning, and less frequently as the participant progresses (Schmidt and Lee,
1999;70 Magil, 200171). As participants benefit from self-learning, progressively decreasing
feedback enables independent problem-solving to enhance motor learning; for MPT,
participants will be aware of when their movement quality is improving as the therapist
will reduce the amount of time during a session where tactile contact and guidance and
provided. Another strategy of fading feedback is by providing bandwidth feedback; this
refers to feedback provided only when performance falls outside the specified criteria.
For example, a person with stroke may use their trunk to reach forward for a cup. The
therapist may want to discourage this compensatory movement and stimulate active
shoulder flexion instead. By touching the participant’s trunk if this moves forward, the
participant will realise their mistake. Note that they only receive this feedback if they do
something wrong, otherwise practice continues with the participant knowing their
performance is correct. This type of feedback promotes consistency of performance
Periodically, it is recommended that a summary of feedback or an average feedback score
is provided to the participant, formulated in constructive terms. An example of summary
feedback is the number of times out of five attempts that the movement was performed
correctly. An example of average feedback is the average number of times that the
participant has their elbow by their side while lifting an object five times. Both of these
methods mean that feedback is not provided after each attempt, but only after a certain
number have been completed. Both summary and average feedback are postulated to be
more effective than feedback provide on every attempt by providing the learner with an
opportunity to process their intrinsic feedback and reduce reliance on augmented feedback
continued
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TABLE 35 Summary and description of MPT (continued )
Brief name MPT
Focus on feedback
Feedback can induce an internal focus of attention in the learner (about the body and
body parts) or an external focus of attention (about effects of the movement on the
environment). Although an external focus feedback may be more effective than internal
focus feedback in healthy people (Wulf and Prinz, 2001;73 McNevin et al., 200374),
it remains uncertain whether or not this is generalisable to stroke survivors. Participants
can be provided with some essential external focus information in order to ensure they
understand the purpose of the activity, but the emphasis is on an internal focus of
attention
Order of activities in each intervention session
Assessment should commence with the whole practice of a functional movement,
using a therapeutic object, to enable the therapist and participant to identify which
components (if any) can be performed normally (with quality). Activities and exercises
are chosen from the selection contained in the Treatment Activities section of the
Manual (see following), using clinical reasoning to determine the content of the
intervention session. There is no predefined order for treatment activities within MPT
Specific therapy activities
1. Soft tissue mobilisation
i. Stroking
ii. Effleurage
iii. Lymph drainage techniques
iv. Petrissage (kneading/wringing/picking up/rolling)
v. Specific compression (trigger points)
vi. Myofascial release
vii. Frictions
2. Joint mobilisation
i. Active movements, not functional
ii. Passive movements
iii. Accessory movements
3. Facilitation of muscle activity/movement
i. Mental imagery
ii. Patient-generated cueing
iii. Therapist-generated cueing
iv. Hands on to induce a desired motor response
v. Active-assisted movement
vi. Facilitation of arm/hand activity from another body part
vii. Restricted use of non-paretic limb
4. Positioning
i. Side lying hemiplegic side
ii. Side lying non-hemiplegic side
iii. Supine lying
iv. Half lying
v. Sitting in armchair
vi. Forwards lean sitting
vii. Sitting in wheelchair
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TABLE 35 Summary and description of MPT (continued )
Brief name MPT
5. Specific sensory input
i. Tactile stimulation (e.g. textures, temperatures, vibration, stroking)
ii. Proprioceptive stimulation (e.g. joint distraction/compression, stereognosis
exercises)
6. Exercises to increase strength
i. Resistance from the therapist
ii. Resistance from body weight
iii. Resistance from equipment
iv. Gravity-neutral repetitive movement
7. Balance and mobility incorporating upper limb activity
i. In or from lying
ii. In or from kneeling
iii. In or from sitting
iv. In or from standing
v. In walking
8. Upper limb functional tasks
i. Bilateral functional activities
ii. Unilateral reaching activities which are object directed
iii. Unilateral reaching activities which are spatially directed
iv. Dexterity exercises (including all grasp and manipulation activities, such as
writing or picking up small objects such as pins/marbles)
9. Education for patient and/or carer
i. To encourage self-monitoring of upper limb with awareness of positioning
and alignment
ii. Transfers training
iii. Limb handling and positioning skills
iv. Written/visual/photo exercise programme
Examples of equipment used:
l Air inflated supports
l Ball
l Balloon
l Beads
l Bed
l Chair
l Coins
l Comb/hairbrush
l Games (Jenga, dominoes, chess, draughts, jigsaw puzzle, cards)
l Gymball
l Jug
l Multigym
l Parallel bars
l Pens/pencils
l Pillows
l Plinth
l Sandbag
l Sensory box
l Small ball
l Table/high table
l Tennis ball, football
l Theraband
continued
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TABLE 35 Summary and description of MPT (continued )
Brief name MPT
l Toothpaste, deodorant
l Towels
l Upper limb bike
l Wedge
Who provided?
For each category of intervention
provider (e.g. psychologist,
nursing assistant), describe their
expertise, background and any
specific training given
MPT is delivered by therapists, providing a strong emphasis on ‘hands-on’ techniques
(therapeutic handling). The therapy is therefore therapist dependent, with an emphasis
on preparation and joint alignment via tactile/proprioceptive input. For the FAST-
INdICATE trial, MPT was provided by qualified senior (UK band 6) physiotherapist or
occupational therapist, or by a junior (UK band 5) therapist under the supervision of a
band 6 therapist. UK ‘band 6′ is an indication of some specialised experience post
qualification. Specific training was given to all trial therapists in understanding the
philosophy behind the intervention, the content of the intervention and how to deliver
the intervention. Training was provided for the group of therapists, and was also
provided on an individual basis. Two follow-up training events were provided for
therapists employed to work in the trial
How?
Describe the modes of delivery
(e.g. face to face or by some
other mechanism, such as
internet or telephone) of the
intervention and whether it was
provided individually or in a
group
Therapy was delivered face to face with the trial participants; for the majority of
treatments, this was on an individual basis. A small number of treatments were
provided in a group situation but the therapy content was personalised. In addition to
face-to-face therapy, some therapist-directed but participant-administered therapy was
delivered; the therapist advised the participant about which exercises or activities
should be done, how they should be done, and for how long (intensity, frequency and
duration). For example, this might include massage and manipulation of the hand, and
practice moving joints and digits in the arm and hand in a controlled manner
Where?
Describe the type(s) of location(s)
where the intervention occurred,
including any necessary
infrastructure or relevant
features
MPT intervention was provided in the hospital ward, hospital out-patient facility or in
the participant’s own home
When and how much?
Describe the number of times
the intervention was delivered
and over what period of time
including the number of
sessions, their schedule, and
their duration, intensity or dose
The MPT intervention was delivered for up to 120 minutes per day, Monday to Friday,
for 6 weeks; this did not include bank holidays. This amounted to a maximum of
30 sessions of treatment. When the participant was not able to tolerate 120 minutes
of therapy in one block of treatment, he or she was provided with directed therapy
that he or she could self-administer later in the day to achieve the 120 minutes of
therapy. An MPT treatment schedule was provided for the therapists to record the
content and intensity (number of minutes) of treatment each day. A trial operating
procedure or treatment manual was provided for therapists to refer to for clarification
and guidance. The treatment schedule and manual are appended (see Appendices 4
and 5)
Tailoring
If the intervention was planned
to be personalised, titrated or
adapted, then describe what,
why, when and how
The intervention was personalised according to the clinical presentation of the
participant each day; clinical decisions were made according to the participant’s
sensorimotor performance/ability and the most-appropriate interventions from the MPT
treatment schedule were selected in an appropriate combination determined by the
skilled therapist. Choice of activities by the therapist is informed by expert assessment
of how much quality voluntary movement can be performed by a participant, where
this becomes difficulty during a functional task, and why this happens. Delivery of
treatment activities is targeted at reducing the blocks to, and enhancing the
performance of, quality movement. Choices are based on a process of clinical
reasoning and problem-solving in relation to the identified movement problem. This
process is undertaken in consultation with individual participants to ensure adherence
to the principles of goal-setting
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TABLE 35 Summary and description of MPT (continued )
Brief name MPT
Modifications
If the intervention was modified
during the course of the study,
describe the changes (what,
why, when and how)
Initially, MPT was referred to as CPT (as detailed in the trial protocol); however,
following further discussion with clinical colleagues, the trial intervention was renamed
MPT because it did not represent all aspects of CPT but focused on movement
performance in the upper limb
How well? Intervention adherence/fidelity was assessed by two members of the Trial Management
Group (VMP and SMH) who observed both trial interventions being provided to
participants at two of the three sites during the trial. In order to maintain fidelity,
training events were organised for all therapists providing trial intervention, and an
internal network for the therapists was set up so that they could seek peer support
and mentorship regarding intervention fidelity
Planned: if intervention
adherence or fidelity was
assessed, describe how
and by whom, and if any
strategies were used to
maintain or improve fidelity,
describe them
Actual: if intervention
adherence or fidelity was
assessed, describe the extent
to which the intervention
was delivered as planned
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1. INTRODUCTION 
1.1. STUDY BACKGROUND 
 
Stroke is the single largest cause of adult disability worldwide. Each year, in England alone, 
approximately 110,000 people suffer a stroke and approximate annual costs are: £2.8 billion direct 
health and social care costs; £1.8 billion to the wider community in terms of lost productivity and 
disability; and £2.4 billion in costs to informal carers. The majority of this cost is the result of 
"rehabilitation and life after stroke". The impact on the NHS is unlikely to fall because the benefits 
of better preventative and acute care are likely to be offset by an increase in the percentage of older 
people in the population to 23% in 2031 (16% in 2003), in whom most strokes occur. Stroke 
rehabilitation is a research priority for the NHS and more widely for Europe. 
It is known that physical therapy for motor impairment after stroke is generally effective, that motor 
recovery occurs most rapidly in the first three months after stroke and that during this period the 
central nervous system (CNS) probably has most potential for reorganisation. Further progress in the 
provision of effective therapy for patients early after stroke requires deeper understanding of the 
process of CNS recovery associated with clinical improvement (mechanisms) and determining which 
physical therapies should be provided (clinical efficacy) for which stroke survivors (prognostic 
indicators). 
Further progress, therefore, requires neurological investigation of the efficacy of well-characterised 
interventions for which proof-of-principle is established, and at the same time using these 
interventions to determine how the CNS responds in the presence of different stroke lesions. This is 
important because there is a need to establish knowledge of mechanism to improve understanding of 
why treatment works or does not work.  
Investigating efficacy and mechanisms together in this Phase II trial will provide robust information 
to ensure that subsequent Phase III trials investigate the effectiveness of functional strength training 
(FST) targeted at the underlying CNS mechanisms of upper limb motor deficits early after stroke in 
those people most likely to respond. This approach is of critical importance in subsequent trials of 
neurorehabilitation interventions so that potentially important clinical effects are not diluted by 
attempting to treat patients for whom other interventions might be more appropriate. More generally, 
the results of this proposed trial, using conventional physicalmovement performance therapy (MPT) 
and FST as probes of CNS recovery, are expected to contribute to knowledge of the CNS mechanisms 
of upper limb recovery after stroke. The need for such research is well recognised. 
1.2. STUDY OBJECTIVES 
The primary driver for this research is the clinical hypothesis that FST for the paretic upper limb plus 
the standard amount of protocol-driven CPT (CPT+FST) produces greater improvements in motor 
impairment and functional ability and is more cost-effective than CPT+MPT in people with upper 
limb motor impairment early after stroke. The objectives are: 
1. To determine whether CPT+FST commenced early after stroke produces greater 
improvements in upper limb motor recovery than CPT+MPT (clinical efficacy)  
2. To identify the similarities and differences in the neural correlates of clinical improvement 
in upper limb motor function in response to (a) CPT+FST and (b) CPT+MPT 
(understanding neural and behavioural mechanisms)  
3. To determine whether any pre-treatment parameters or any combination of pre-treatment 
parameters; (a) clinical severity, (b) anatomical location/volume of infarction (derived from 
structural brain imaging), (c) residual functional anatomy (derived from fMRI), (d) residual 
structural cortico-cortical and cortico-spinal connectivity (derived from DTI), and (e) brain-
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muscle functional connectivity (derived from TMS), are sufficiently predictive of 
improvement in upper limb motor function to enable physical therapy to be targeted at those 
stroke survivors most likely to respond (new scientific/clinical principles)  
A further objective on cost-effectiveness is not part of the Robertson Centre analysis.   
1.3. STUDY DESIGN 
The FAST INDICATE trial is a randomised, controlled, observer-blind, 2-group, multi-centre Phase 
II trial to determine efficacy of CPT+FSTcompared with CPT+MPT for enhancing upper limb 
recovery, with embedded explanatory measures to determine prognostic indicators for and neural 
correlates of response to CPT+FST and CPT+MPT.   
Randomisation was stratified by clinical cenre, time after stroke (up to 30 days and 31-60 days) and 
ability to use the paretic upper limb as assessed by the Nine Hole Peg Test (1 peg or less and 2-8 
pegs). 
1.4. SAMPLE SIZE AND POWER 
The protocol (section ‘Sample size’) states: 
The minimum clinically important change in ARAT score of around 6 points translates to an 
improvement of one level on 6 of the 19 upper limb tasks tested. There are no intra-class correlation 
coefficient (ICC) estimates in the literature for physiotherapy interventions being assessed using any 
of our proposed outcomes. ICC values are known to be lower where patient rather than process of 
care outcomes are being measured, with the ICC being expected to be somewhat lower than 0.05 for 
patient outcomes. This sample size calculation is based on actual ARAT data from our previous early 
phase trial. Assuming an ICC of 0.01 in both treatment arms and three centres with a separate therapist 
for each randomised arm, a sample size of 99 participants per group would have 80% power to detect 
a clinically important mean difference of 6.2 in ARAT change when analysing data using a two 
sample t-test, with Satterthwaite correction, applying a 5% 2-sided significance level and allowing 
for potentially different standard deviations in the CPT+MPT (7.9) and CPT+FST (19.3) groups. To 
account for clustering in the design (participants within therapist within randomised treatment at each 
study site) a sample size inflation factor 1+(m-1)*ICC is applied where m is the cluster size and ICC 
is the intra-class correlation coefficient. We have investigated this using the SSC software (Health 
Services Research Unit, University of Aberdeen). Here we have three study sites each with two 
therapists. Assuming that recruitment is evenly distributed across therapists, the sample size is 
therefore inflated to 129 evaluable participants per group. The corresponding mean differences in 
ARAT change that would be detectable in a study of this size for ICCs of 0.02 and 0.03 would be 7.0 
and 7.8 respectively, showing that the design is fairly insensitive to assumptions about the ICC. 
Finally, to allow for an attrition rate of 10%, 144 participants per groups will be recruited – total 
sample size of 288. 
1.5. DEVIATONS FROM THE PROTOCOL 
The protocol noted that the analysis methods to be employed would take into account the clustering 
aspect of the study.  However, due to logistical issues the proposed clustering structure (patients 
within therapist within treatment group) was not carried out for all patients.  Therefore the analysis 
methods noted in the protocol (which took account of the clustering) are no longer valid.  All analyses 
will therefore be carried out as CPT+MPT vs CPT+FST with no clustering. 
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1.6. STUDY POPULATION 
Potential study subjects were screened from either acute in-patient or rehabilitation settings in 
services provided around Birmingham, North Staffordshire and Norfolk.   
1.6.1. INCLUSION CRITERIA (AS NOTED IN THE PROTOCOL) 
1. adults aged 18+ years,  
2. 2 - 60 days after stroke when they provide informed consent. This time period has been 
chosen because some people who may meet the criteria for this trial are discharged from 
stroke services a few days after stroke and they need to be provided with the opportunity to 
participate. As brain recovery occurs mostly in the first 3 months after stroke participants 
will be within what is considered to be the critical time window for neural re-organisation;  
3. stroke in anterior cerebral circulation territory, cortical and/or subcortical, confirmed by 
clinical neuroimaging;  
4. sufficient voluntary muscle contraction in the paretic upper limb to generate the beginning 
of prehension i.e score at least 11/33 for Motricity Index pinch section;  
5. unable to complete the Nine Hole Peg Test (9HPT) in 50 seconds or less (maximum time for 
test);  
6. no obvious spatial neglect as defined by a score of 0 or 1 on the Extinction and Inattention 
sub-scale of the NIH Stroke Scale.  
7. have no obvious motor dyspraxia or communication deficits as assessed by ability to imitate 
action with the non-paretic upper limb. This will be assessed by the Research Therapist 
sitting alongside the potential participant. The Research Therapist will perform 5 upper limb 
activities and potential subjects will be asked to observe with intent to imitate and then 
perform the activities. The accuracy of imitation of observed activity will be assessed on the 
3-point scale used by Decety[41]: 2 = correctly reproduced action; 1 = incorrectly 
reproduced action; 0 = not reproduced. Those scoring 8/10 or above will be considered to 
have the ability to imitate and therefore be included in this proposed trial;  
8. were able, prior to the index stroke, to use the paretic upper limb to lift a cup and drink from 
it;  
1.7. STATISTICAL ANALYSIS PLAN (SAP) 
1.7.1. SAP OBJECTIVES 
The objective of this SAP is to describe the statistical analyses to be carried out by the Robertson 
Centre for Biostatistics (RCB) for the final analyses of the FAST INDICATE study. 
1.7.2. GENERAL PRINCIPLES 
All study data will be summarised at entry to the study, after the treatment period (week 6) and after 
the follow-up period (month 6).  Categorical variables will be summarised with the number and 
proportion of subjects falling in each category as well as the number missing. Continuous variables 
will be summarised using the number of observations, the number of missing values, mean, median, 
standard deviation (SD), lower quartile, upper quartile, minimum and maximum values. 
DOI: 10.3310/eme05030 EFFICACY AND MECHANISM EVALUATION 2018 VOL. 5 NO. 3
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Pomeroy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
73
All statistical tests will be performed using two-sided tests at the 5% level of statistical significance. 
1.7.3. CURRENT PROTOCOL 
The current study protocol at the time of writing is version 7.3, dated 15th May 2015.  Any updates to 
the protocol after the approval of this version of the SAP, will be reviewed for their impact on this 
SAP, which will only be updated if the changes to the protocol require it.  If no changes are required 
to this SAP following future amendments to the study protocol, this will be documented as part of the 
Robertson Centre Change Impact Assessment processes. 
1.7.4. SOFTWARE 
Data will be analysed using SAS for Windows v9.2 or later. 
2. ANALYSIS 
2.1. STUDY POPULATIONS 
The randomised set (RS) consists of all randomised subjects who will be analysed according to the 
group to which they were randomly allocated. 
 
2.2. BASELINE CHARACTERISTICS 
No formal statistical analyses will be carried out on the baseline data.  Baseline characteristics will 
be summarised for each randomised treatment group separately and overall.  
The following baseline characteristics will be reported: 
 
Demographic characteristics  
• Age (years) 
• Sex 
 
Randomisation strata 
• Time after stroke (<=30 days, 31-60 days) 
• Ability to use paretic upper limb (1 peg or less, 2-8 pegs) 
• Clinical centre 
 
Medical History  
• Type of stroke  
• More paretic side of body 
• Site of brain lesion 
 
2.3. EFFICACY ANALYSES 
2.3.1. FIRST OBJECTIVE - CLINICAL EFFICACY  
 
To answer the first objective, the primary analysis will compare the change in the efficacy 
parameters (baseline and week 6) between the treatment groups. 
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Change in the efficacy parameters (ARAT paretic, ARAT non-paretic, Hand Grip Force, Pinch Grip 
force, Wolf Motor Function Test (WMFT) – total functional score and 15 individual functional 
scores, EQ-5D total score, EQ-5D VAS) at week 6 will be analysed using analysis of covariance 
(ANCOVA) models adjusted for the baseline value and randomisation strata (time after stroke, 
ability to use paretic upper limb, clinical centre).  Adjusted least square means difference and 95% 
confidence intervals (CIs) will be reported. 
Where the outcome distribution deviates from a normal distribution, a log or other appropriate 
transformation will be applied.   
Changes from baseline at month 6 will be analysed as for week 6 changes. 
2.3.2. SECOND OBJECTIVE – MECHANISMS (EXPLANATORY MEASURES)  
To answer the second objective, associations between the changes in TMS and MRI variables will be 
compared to the changes in clinical efficacy measures (baseline to week 6).  The clinical efficacy 
measures of interest are WMFT total score, ARAT – paretic, pinch force and grip force.  Correlations 
will be carried out for the two treatment groups separately and for the groups combined: 
 
The following TMS/MRI variables will be analysed: 
• MRI: Volume of stroke lesion 
• MRI: Cortico-cortico anatomical connectivity: FA MNI corpus callosum midline 
• MRI: Cortico-cortico anatomical connectivity: Asymmetry 
ipsilesional:contralesional MNI CSTS 
• TMS: Motor Evoked Potential (MEP) – Biceps paretic (percentage of stimulator 
output at threshold) 
• TMS: MEP – Extensor Carpi Radialis paretic (percentage of stimulator output at 
threshold) 
• TMS: Motor Evoked Potential (MEP) – Biceps non-paretic (percentage of stimulator 
output at threshold) 
• TMS: MEP – Extensor Carpi Radialis non-paretic (percentage of stimulator output at 
threshold) 
In addition, the above TMS and MRI data at baseline, week 6 and change will be summarised and 
compared between the two treatment groups. 
2.3.3. THIRD OBJECTIVE  – MECHANISMS (EXPLANATORY MEASURES) 
To answer the third objective, subgroup analyses will be carried out for the change in ARAT paretic 
at week 6.   
The subgroups of interest are the following baseline variables: 
• MRI: MNI CST Affected (yes/no) 
• MRI: Volume of stroke lesion (above/below median) 
• MRI: Cortico-cortico anatomical connectivity: FA MNI corpus callosum midline 
(above/below median)   
• MRI: Cortico-cortico anatomical connectivity: Asymmetry 
ipsilesional:contralesional MNI CSTS (above/below median) 
• TMS: MEP – Biceps paretic (yes/no) 
• TMS: MEP – Extensor Carpi Radialis paretic (yes/no) 
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The treatment effect will be calculated within each level of the subgroup (adjusted as for the first 
objective) and an interaction term for randomised treatment and baseline covariate will be included 
in the model. 
2.4. SAFETY OUTCOMES 
2.4.1. STUDY DISPOSITION 
Patient disposition by treatment group will be reported with reasons for withdrawal from study: 
• Adverse event (non-serious) 
• Participant unwilling to continue in study activities 
• Participant withdrew consent  
• Participant withdrawn on advice of investigator 
• Participant lost to follow-up 
• Other 
2.4.2. ADVERSE EVENTS 
Adverse events will be reported in two phases: during the treatment period (start date on or after 
randomisation date and less than week 6 visit date) and during the follow up phase (start date on or 
after week 6 visit date). 
Adverse events will be summarised by treatment group, ordered by system organ class and preferred 
term.   
The following adverse events will be summarised: 
• Adverse events 
• Related adverse events 
• Serious adverse events  
• Unexpected serious adverse events  
2.4.3. ADVERSE REACTIONS 
The number and percentage of subjects with adverse reactions for pain and fatigue will be reported 
in two phases: during the treatment period and during the follow up phase (as defined for the adverse 
events in section 2.4.2). 
3. DERIVED VARIABLES 
Age is calculated as: (Randomisation date – date of birth)/365.25 
ARAT will be calculated according to the validated score sheet.   
Grip force and pinch force will be analysed as the maximum out of the (up to ) three measurements 
taken at each visit. 
Pain – reported on four consecutive visits (either behavioural or verbal) and this is confirmed as an 
adverse event during each phase 
Fatigue – two consecutive visits where the fatigue is confirmed as an adverse event during each phase 
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Related adverse events – any adverse event reported with a causality of ‘definitely’, ‘likely’ or 
‘possibly’ related.  Events with a missing causality will be considered as ‘related’. 
EQ5D score – each of the 5 questions are scored as 1, 2 or 3 in the case report form and the standard 
weighted score is assigned.
The weighted scores are calculated by subtracting the relevant weight coefficients from 1 (Perfect 
health).  The constant term is used if there is any item with a response greater than level 1.  The N3 
term is used if any item is at level 3.  For example, the algorithm for computing the score for the 
health state 21223 is: 
1 - (0.081 + 0.069 + 0 + 0.036 + 0.123 + 0.236 + 0.269) = 0.186 
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4. DATA LISTINGS 
No listings will be provided in the report.  An excel file (or files) will be created containing all the 
data in the database (including derived calculations) to be sent to the Chief Investigator. 
5. DOCUMENT HISTORY 
This is version 1.0 of the statistical analysis plan, initial creation. 
6. TABLE SHELLS 
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Protocol: FAST INDICATE                                                       
Population: Randomised 
 
Table 1.1 
Randomisation details, by treatment group and overall 
  
Variable Statistic Treatment 
A 
(n= XXX) 
Treatment 
B 
(n= XXX) 
All 
(n= XXX) 
Time after stroke N XX XX XX 
<= 30 days XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%) 
31-60 days XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%) 
     
Ability to use 
paretic upper limb 
N XX XX XX 
1 peg or less XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%) 
2-8 pegs XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%) 
     
Site N XX XX XX 
Birmingham XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%) 
Norwich XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%) 
Staffordshire XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%) 
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Protocol: FAST INDICATE                                                       
Population: Randomised  
 
Table 1.2 
Demographic characteristics 
 
Variable Statistic Treatment 
A 
(n= XXX) 
Treatment 
B 
(n= XXX) 
All 
(n= XXX) 
Age (years) N XX XX XX 
Mean XX.X XX.X XX.X 
Std Dev XX.XX XX.XX XX.XX 
Median XX.X XX.X XX.X 
Min – Max XX – XX XX – XX XX – XX 
Interquartile 
range 
XX – XX XX – XX XX – XX 
Missing XX XX XX 
     
Gender N XX XX XX 
Male XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
Female XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
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Protocol: FAST INDICATE                                                       
Population: Randomised  
 
Table 1.3 
Medical history 
 
Variable Statistic Treatment 
A 
(n= XXX) 
Treatment 
B 
(n= XXX) 
All 
(n= XXX) 
Type of stroke N XX XX XX 
Ischaemic XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
Haemorrhagic XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
     
More paretic 
side of the body 
N XX XX XX 
Left XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
Right XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
     
Side of brain 
lesion 
N XX XX XX 
Left XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
Right XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
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Protocol: FAST INDICATE                                                       
Population: Randomised  
 
Table 2.1a 
ARAT during the study – non-paretic  
 
Variable Statistic Treatment 
A 
(n= XXX) 
Treatment 
B 
(n= XXX) 
All 
(n= XXX) 
Baseline N XX XX XX 
 Mean XX.X XX.X XX.X 
Std Dev XX.XX XX.XX XX.XX 
Median XX.X XX.X XX.X 
Min – Max XX – XX XX – XX XX – XX 
Interquartile 
range 
XX – XX XX – XX XX – XX 
Missing XX XX XX 
     
Week 6 N XX XX XX 
Mean XX.X XX.X XX.X 
Std Dev XX.XX XX.XX XX.XX 
Median XX.X XX.X XX.X 
Min – Max XX – XX XX – XX XX – XX 
Interquartile 
range 
XX – XX XX – XX XX – XX 
Missing XX XX XX 
     
Month 6 N XX XX XX 
Mean XX.X XX.X XX.X 
Std Dev XX.XX XX.XX XX.XX 
Median XX.X XX.X XX.X 
Min – Max XX – XX XX – XX XX – XX 
Interquartile 
range 
XX – XX XX – XX XX – XX 
Missing XX XX XX 
 
Similar tables to table 2.a: 
Table 2.1b – ARAT paretic 
Table 2.1c – Grip force 
Table 2.1d – Pinch force 
Table 2.1e – WMFT total score 
Table 2.1f1 to 2.1f15 – WMFT functional scores 
Table 2.1g – EQ5D score 
Table 2.1h – EQ5D VAS 
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Protocol: FAST INDICATE                                                       
Population: Randomised  
Table 2.2a 
Change (Visit 2 – Visit 1) in ARAT non-paretic during the study  
Visit 2 
– Visit 
1 
Treatmen
t 
Numbe
r 
with 
data 
at 
both 
visit
s 
Mean 
(std) 
at 
Visit 
1 
Mean 
(std) 
at 
Visit 
2 
Change
, mean 
(std) 
Least 
squares 
mean 
differenc
e (95% 
confidenc
e 
interval) 
of change 
between 
treatment 
groups  
P-
value 
Week 6 
– 
baselin
e 
A XX XX.X 
(XX.XX
) 
XX.X 
(XX.XX
) 
XX.X 
(XX.XX
) 
X.X (X.X, 
X.X) 
0.XXX
X 
B XX XX.X 
(XX.XX
) 
XX.X 
(XX.XX
) 
XX.X 
(XX.XX
) 
        
Month 6 
– 
baselin
e 
A XX XX.X 
(XX.XX
) 
XX.X 
(XX.XX
) 
XX.X 
(XX.XX
) 
X.X (X.X, 
X.X) 
0.XXX
X 
B XX XX.X 
(XX.XX
) 
XX.X 
(XX.XX
) 
XX.X 
(XX.XX
) 
        
 
Only reported for subjects with data at both visits 
 
Similar tables to table 2.2a: 
Table 2.2b – ARAT paretic 
Table 2.2c – Grip force 
Table 2.2d – Pinch force 
Table 2.2e – WMFT total score 
Table 2.2f1 to 2.2f15 – WMFT functional scores 
Table 2.2g – EQ5D score 
Table 2.2h – EQ5D VAS 
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Protocol: FAST INDICATE                                                       
Population: Randomised  
 
Table 2.3a 
Correlations (change from baseline to week 6) for MRI: Volume of 
stroke lesion  
 
Clinical Efficacy 
Variable 
Statistic Treatment 
A 
(n= XXX) 
Treatment 
B 
(n= XXX) 
All 
(n= XXX) 
 WMFT total score Correlation co-
efficient 
P-value 
X.XXXX 
0.xxxx 
X.XXXX 
0.xxxx 
X.XXXX 
0.xxxx 
 ARAT paretic Correlation co-
efficient 
P-value 
X.XXXX 
0.xxxx 
X.XXXX 
0.xxxx 
X.XXXX 
0.xxxx 
 Pinch force Correlation co-
efficient 
P-value 
X.XXXX 
0.xxxx 
X.XXXX 
0.xxxx 
X.XXXX 
0.xxxx 
 Grip force Correlation co-
efficient 
P-value 
X.XXXX 
0.xxxx 
X.XXXX 
0.xxxx 
X.XXXX 
0.xxxx 
 
Similar tables to table 2.3a: 
Table 2.3b – MRI: Cortico-cortico anatomical connectivity: FA MNI 
corpus callosum midline 
Table 2.3c - MRI: Cortico-cortico anatomical connectivity: Asymmetry 
ipsilesional:contralesional MNI CSTS 
Table 2.3d – TMS: MEP – Biceps paretic (percentage of stimulator 
output at threshold) 
Table 2.3e – TMS: MEP – Extensor Carpi Radialis paretic (percentage 
of stimulator output at threshold) 
Table 2.3f – TMS: MEP – Biceps non-paretic (percentage of stimulator 
output at threshold) 
Table 2.3g – TMS: MEP – Extensor Carpi Radialis non-paretic 
(percentage of stimulator output at threshold) 
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Similar tables to table 2.1a/2.2a (baseline and week 6 only): 
Table 2.4a/2.5a – MRI: Volume of stroke lesion 
Table 2.4b/2.5b  – MRI: Cortico-cortico anatomical connectivity: FA 
MNI corpus callosum midline 
Table 2.4c/2.5c  - MRI: Cortico-cortico anatomical connectivity: 
Asymmetry ipsilesional:contralesional MNI CSTS 
Table 2.4d/2.5d  – TMS: MEP – Biceps paretic (percentage of 
stimulator output at threshold) 
Table 2.4e/2.5e  – TMS: MEP – Extensor Carpi Radialis paretic 
(percentage of stimulator output at threshold) 
Table 2.4f/2.5f  – TMS: MEP – Biceps non-paretic (percentage of 
stimulator output at threshold) 
Table 2.4g/2.5g  – TMS: MEP – Extensor Carpi Radialis non-paretic 
(percentage of stimulator output at threshold) 
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Similar tables to table 2.2b (ARAT paretic, baseline and week 6 
only) will be produced for each level of the subgroup variables: 
Table 2.6a – MRI: MNI CST Affected (no) 
Table 2.6b – MRI: MNI CST Affected (yes) 
Table 2.7a – MRI: Volume of stroke lesion (below median) 
Table 2.7b – MRI: Volume of stroke lesion (above median) 
Table 2.8a – MRI: Cortico-cortico anatomical connectivity: FA MNI 
corpus callosum midline (below median) 
Table 2.8b – MRI: Cortico-cortico anatomical connectivity: FA MNI 
corpus callosum midline (above median) 
Table 2.9a - MRI: Cortico-cortico anatomical connectivity: Asymmetry 
ipsilesional:contralesional MNI CSTS (below median) 
Table 2.9b - MRI: Cortico-cortico anatomical connectivity: Asymmetry 
ipsilesional:contralesional MNI CSTS (above median) 
Table 2.10a – TMS: MEP – Biceps paretic (no) 
Table 2.10b – TMS: MEP – Biceps paretic (yes) 
Table 2.11a – TMS: MEP – Biceps paretic percentage of stimulator 
output at threshold (below median) 
Table 2.11b – TMS: MEP – Biceps paretic percentage of stimulator 
output at threshold (above median) 
Table 2.12a – TMS: MEP – Extensor Carpi Radialis paretic (no) 
Table 2.12b – TMS: MEP – Extensor Carpi Radialis paretic (yes) 
Table 2.13a – TMS: MEP – Extensor Carpi Radialis paretic percentage 
of stimulator output at threshold (below median) 
Table 2.13a – TMS: MEP – Extensor Carpi Radialis paretic percentage 
of stimulator output at threshold (above median)
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FAST Indicate Study worksheet: Randomisation 
 
IMPORTANT:  
- Please ensure that you have gathered all information required before making a call to the system.  
- Steps will proceed sequentially unless otherwise noted. 
Step Voice Prompt Data values Value entered 
1 Welcome to the FAST Indicate Study IVRS   
  
2 Please enter your Site ID Site ID        
 The Site ID will be checked for validity. If the Site ID does not exist an error message will result: “The Site ID you entered was 
not recognised. Please try again.” and step 2 will be repeated. 
3 Please enter your PIN PIN                 
 Your PIN will be checked for validity. If the PIN does not exist in the system an error message will result: “The PIN you entered 
was not recognised” will play and you will be sent back to the start of step 3. 
4 Menu options 
To Randomise a patient, press 1 
Menu choice  1  
  
5 Please enter the Screening Number of the patient that 
you want to randomise 
       /              
 • If an invalid response is given then the message “You entered an invalid value. Please try again.” will play and you will be 
sent back to the start of step 5. 
• If a valid Screening Number is entered and it has not already been randomised then proceed to step 6. 
• If a valid Screening Number is entered but it has already been randomised on the system then the message “The Screening 
Number you entered has already been randomised. To randomise a patient with a different Screening Number press 1 or 
press any other button to end the call.” will play. Pressing 1 in response to this message will return you to the start of step 
5. Any other button will end the call. 
6 Please specify the Time After Stroke: 
Press 1 for <= 30 days 
Press 2 for 31-60 days 
 
Time After 
Stroke     
 Range: 1 (<=30 days) or 2 (31-60 days) 
If an invalid value (non-numeric) or out of range value is entered you will be notified and asked to repeat this step. 
7 Please specify the patient’s ability to use 
paretic upper limb as assessed by 9HPT: 
Press 1 for “1 peg or less (in 50 seconds)”  
Press 2 for “2-8 pegs (in 50 seconds)”  
 
9HPT     
 Range: 1 (1 peg or less) or 2 (2-8 pegs) 
If an invalid value (non-numeric) or out of range value is entered you will be notified and asked to repeat this step. 
8 You have now entered all values required to randomise 
the patient. Press 1 to continue with randomisation; 
Press 2 to review all the values you have just entered; or 
Press 3 to end the call without randomising  
 Enter: 
1, 2 or 3 
as appropriate  
 Instructions:  Pressing 1 will take you to step 9. If any errors occur at the randomisation step a message will play back with 
specific details of the error and the call will then end. 
 Pressing 2 will play back a summary of all the values you entered above. The option will then be given to go 
back and re-enter the values again (Option 2) or to continue with the randomisation process (Option 1). Selecting 
2 will return you to step 5, selecting 1 will proceed to step 9. 
 Pressing 3 ends the call 
Range:  1, 2 or 3 
DOI: 10.3310/eme05030 EFFICACY AND MECHANISM EVALUATION 2018 VOL. 5 NO. 3
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Pomeroy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
109
141 of 144
9 The patient with Screening Number       /             has been 
successfully randomised and has been allocated:  
 
Randomisation Number                
with treatment group      CPT + CPT 
         CPT + FST 
 
 
  
10 To hear this information again press 1 or press any 
other button to end the call  
 Enter: 
1 to hear details in 9 
again; 
any other button to end 
the call 
 Range:  1 – hear again; any other button – end call 
11 Thank you for calling goodbye    
Version Date Description Created by 
Draft 1 05/09/2012 Initial version release Robbie Wilson 
1.0 12/09/2012 Updated to add IVRS number and amend incorrect step 
numbers 
Sarah Weeden 
1.1 02/10/2012 Updated to provide live IVRS number following release 
of live system 
Sarah Weeden 
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